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ABSTRACT 
 
Atopic dermatitis (AD) is a common, complex 
inflammatory skin disorder where a defect skin 
barrier is central in the pathogenesis. Mutations 
in the filaggrin gene cause ichthyosis vulgaris 
(IV). IV is one of several keratinization 
disorders named ichthyoses where mutations in 
skin barrier genes are a common underlying 
genetic factor. Furthermore, filaggrin mutations 
are a major risk factor for moderate to severe 
AD. The aim of the work reported in this thesis 
is to improve the understanding of the genetic 
mechanisms of skin barrier defects associated 
with AD, and to identify whether AD and other 
common disorders of keratinisation may share 
genetic susceptibility factors related to skin 
barrier dysfunction. Paper I presents data 
suggesting that filaggrin mutations may be rare 
in Ethiopian AD and IV patients, implying other 
mechanisms should be more important in the 
pathogenesis of IV and AD in this ethnic group. 
Paper II presents a novel mutation in the steroid 
sulfatase gene in a patient with clinical signs of 
common ichthyosis type. In paper III 
association between filaggrin mutations and 
childhood onset of psoriasis was tested. No 
association to any prevalent filaggrin mutations 
was found, and no novel mutations. This 
indicates that filaggrin loss-of- function variants 
do not have a strong effect on the onset of 
psoriasis in childhood.  
 
 
In paper IV it is demonstrated that functional 
parameters and gene expression in molecular 
pathways in vivo is altered in patients suffering 
from AD and IV and depend on filaggrin 
genotype. Patients with filaggrin mutations 
displayed a severe phenotype with impaired 
barrier function measured as increased trans-
epidermal water loss, and significantly altered 
pH levels. Furthermore, the numbers of genes 
with altered expression were significantly higher 
in patients with low or absent filaggrin 
expression. These pathways include many genes 
involved in inflammation, epidermal 
differentiation, lipid metabolism, cell signalling 
and adhesion. Paper V represents a candidate 
gene study where expression analysis links the 
epidermal transglutaminases 1 and 3 to the 
manifestation of AD and genetic analysis 
suggests that genetic variation at the 
transglutaminase 1 locus could be involved in 
the development of the disease.  
The results of the work reported in this thesis 
provides additional descriptive information and 
further elucidates the pathogenesis underlying 
AD and other disorders of keratinization, in 
particular in relation to filaggrin deficiency. 
Better understanding of the genetic factors and 
molecular and functional consequences should 
hopefully enable future individually designed 
barrier restoring therapy. 
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1 INTRODUCTION 
1.1 GENES, CHROMOSOMES AND 
MUTATIONS 
Deoxyribonucleic acid (DNA) molecules can be 
found organized in chromosomes of the nucleus 
and in the mitochondria of eukaryotic cells. 
DNA consists of large polymers with a linear 
backbone of sugar and phosphate residues. The 
sugar part consists of deoxyribose and additional 
sugar residues are linked by phosphodiester-
bonds. Attached to a carbon atom in each sugar 
residue is a nitrogen base, consisting of adenine 
(A), cytosine (C), guanine (G) or thymine (T). A 
sugar with its attached base is called nucleoside, 
whereas a nucleotide is a nucleoside with a 
phosphate group attached. This is the basic 
repeating unit of a DNA strand. The composition 
of a ribonucleic acid (RNA) molecule is similar 
to that of a DNA, but RNA contain ribose sugar 
residues instead of deoxyribose, and uracil (U) 
as nitrogen base instead of thymine (T). Whereas 
RNA molecules exist as single strands, the 
structure of DNA is a double helix, where two 
DNA strands are bound together by hydrogen 
bonds. Hydrogen bonding occurs between 
opposed bases of the two strands according to 
the rules of Watson-Crick. A specifically binds 
to T and C specifically binds to G. As a 
consequence, the base composition of DNA is 
not random, the amount of A equals that of T, 
and the amount of C equals that of G (1). Human 
genome is the term describing the total genetic 
information (DNA content) in human cells. The 
majority of the genome is in the nucleus and a 
minority in the mitochondrial genome. A gene is 
a functional nucleotide sequence in a certain 
position on a chromosome, and the majority 
encodes a specific product (e.g. a protein). The 
human genome contains approximately 21000 
genes coding for proteins or functional RNA, 
distributed on 24 chromosomes (22 autosomes 
and two sex chromosomes, X and Y) (2). Each 
chromosome contains one single DNA molecule 
tightly packed by histones and other proteins 
(Fig 1). 
 
 
 
Figure 1: Schematic overview of the 
structural organization of the human 
genome. DNA molecules have a linear 
backbone of sugar phosphate and attached 
bases consisting of either A, C, G or T. DNA is 
structured as a double helix condensed around 
histone proteins forming chromosomes. The 
genome is contained in 24 chromosomes (22 
autosomes and two sex chromosomes, X and Y) 
and exists in the nucleus in eukaryotic cells. In 
addition, the mitochondria located in the 
cytoplasm contain DNA coding for mitochondrial 
genes. Figure modified from the National Human 
Genome Research Institute.  
 
The expression of genetic information in 
eukaryotic cells is largely a one-way system: 
DNA stored on chromosomes in the cell nuclei 
is transcribed into synthesis of messenger RNA 
(mRNA). MRNA in turn is transported into the 
cytoplasm and translated into protein. This flow 
of genetic information has been described as the 
central dogma of molecular biology (3). A set of 
three nucleotides is called a codon, and encodes 
one amino acid, which constitutes the basic 
repeating structure of a protein. Specific start 
and stop codons encode start and termination of 
translation into proteins.  
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Cells in an organism are able to divide and 
replicate their genetic content. This process is 
called mitosis. When gametes are formed (sperm 
and egg cells) a specialized form of cell division 
occurs called meiosis. Each pair of 
chromosomes is separated prior to replication. 
During meiosis exchange of genetic material 
occur between maternal and paternal 
chromosomes. This is called crossing-over or 
recombination and is a principal mechanism for 
increasing genetic admixture between 
generations. On the autosomes two copies of 
each gene are inherited from the parents; a gene 
may thus exist in two alternative forms (alleles). 
An individual with two identical alleles at a 
certain region (locus) is said to be homozygous 
for that allele, whereas an individual with two 
different alleles are said to be heterozygous (3). 
 
The human DNA is not static; it is subject to a 
variety of different types of heritable or acquired 
changes. Larger scale changes can include loss, 
gain or rearrangements of parts of or entire 
chromosomes, whereas smaller scale changes 
may be grouped into subclasses depending on 
the outcome on the adjacent DNA sequence. 
Base substitutions usually include the 
replacement of a single base. Deletions mean 
that one or several nucleotides have been lost 
from the sequence and insertions that of one or 
more nucleotides has been added to a sequence. 
Variations in a DNA sequence that are fairly 
common (at least 1 %) are called polymorphisms 
(4). Polymorphisms affecting a single nucleotide 
are commonly referred to as single nucleotide 
polymorphisms (SNPs).  
 
Changes in base constitution with lower 
frequency in the populations and that may have a 
pathogenic effect are called mutations. They can 
range in size from a single base to a large 
segment of a chromosome. Gene mutations can 
either be inherited, or arise de novo. Common 
chromosomal aberrations include insertions, 
deletions, translocations and inversions. Such 
mutations are often pathogenic. Mutations in a 
single gene have varying effects on health, 
depending on whether they alter function of 
essential proteins. These types of mutations 
include missense mutations (DNA base change 
resulting in an amino-acid substitution), 
nonsense mutations (DNA base change resulting 
in a stop-codon and ending translation) and 
frame-shift mutations (shifts the reading frame 
for the three bases encoding one amino acid). 
DNA base changes underling these mutations 
are frequently caused by insertions, deletions or 
duplications. Mutations may be “silent” in the 
sense that there is no known effect for the 
individual. Only a small percentage of gene 
mutations cause genetic disorders, most do not 
affect health. Also, potential pathogenic 
mutations are often repaired enzymatically prior 
to protein expression. A very small proportion 
may in fact have a positive effect and thus 
driving evolution of the species. This can for 
instance be achieved by an altered expressed 
protein that may have improved or changed 
function that better help the organism to adapt to 
environmental changes (5).  
 
1.1.1 Genetics of inherited diseases 
Inherited genetic diseases can be divided into 
monogenic and multifactorial (complex) 
diseases. Monogenic phenotypes or disorders are 
those whose presence or absence depends on the 
genotype at a single locus. They follow 
Mendelian inheritance laws and a phenotype is 
said to be inherited dominantly if present in a 
heterozygote carrier of a certain genotype, and 
recessive if manifesting only in a homozygous 
individual (3). There is a strong correlation 
between phenotype and genotype in these 
disorders and they can often be recognized by 
the characteristic inheritance pattern they give 
rise to.  
 
Complex diseases do not follow Mendelian 
inheritance laws. They are common, and may be 
both polygenic (multiple susceptibility genes) 
and/or multifactorial (multiple genes interacting 
with environmental factors). Polygenic 
interaction may be explained by an additive or a 
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multiplicative model. The effect of two or more 
genes can equal the sum of their independent 
effect (additive); or the genes can interact in a 
way that results in a greater risk than that posed 
by each gene independently (multiplicative) (6). 
Individual genes behind complex diseases are 
not likely to be either necessary or sufficient for 
manifestation of the disease but, rather, a 
combination of susceptibility genes increases the 
disease risk. In fact, individuals with the same 
phenotype may have different combinations of 
risk-increasing genes and environmental factors. 
Such genetic variations underlying a similar 
phenotype are called genetic heterogeneity, and 
when involving different loci epistasis. 
Individuals may also have an inherited 
susceptibility allele without manifesting the 
disease. This phenomenon is called incomplete 
penetrance. All of these parameters have to be 
taken into account when investigating the 
genetic background underlying complex traits 
such as atopic dermatitis (7). 
 
1.1.2 Linkage disequilibrium and 
haplotypes 
One powerful approach to identify genetic 
factors behind complex diseases has been to 
study association between disease and genetic 
markers. Linkage disequilibrium (LD) is the 
non-random association of alleles between 
genetic loci, which occur when loci are located 
close on the same chromosome and therefore are 
not or only rarely separated by crossing over (8). 
It has been of great significance to understand 
the patterns of LD for the implementation of 
candidate gene studies and then genome-wide 
association studies (GWAS). These rely on the 
ability of genotyping of markers such as SNPs to 
trace other genetic variation, associated with 
underlying diseases (9, 10). The strength of the 
LD between two markers is influenced by 
intrinsic factors like recombination and mutation 
rates, but also extrinsic aspects such as 
population size, admixture and selection. Nearby 
alleles on the same chromosome tend to be 
together as a block. Such a linked block of 
alleles is called a haplotype. Polymorphisms that 
uniquely identify distinct haplotypes are called 
tagging SNP and may hence be used to reduce 
the number of SNPs analyzed.  
 
1.2 THE SKIN 
All organisms have an outer layer that delimits 
the body and separates it from the environment. 
In humans this outer layer is the skin and the 
intestine. The skin is the largest organ of the 
human body. Main functions include protection 
against physical damage, defense against 
biological invasion, regulation of molecular 
passage and signal transmission (7, 11). This 
finely tuned balance between protection from 
harmful pathogens and bidirectional signal 
exchange is provided by a network of structural, 
cellular, and molecular elements, collectively 
referred to as the skin barrier. 
 
1.2.1 Embryological origin and 
anatomy of the skin 
The skin is divided into three principal layers, 
the epidermis, the dermis and the subcutis. The 
skin arises from two major embryological 
elements, the prospective epidermis from the 
early gastrula, and the prospective mesoderm 
which is brought into contact with epidermis 
during gastrulation. The mesoderm provides the 
dermis and is essential for inducing 
differentiation of epidermal structures such as 
hair follicles. The dermis in turn subsequently 
also forms the subcutis (11).  
 
The major cell in epidermis is the keratinocyte, 
95 % of the total. The keratinocyte moves 
progressively from the epidermal basement 
membrane towards the skin surface, forming 
several distinct layers during this process 
(keratinization), forming stratified squamous 
epithelium. The epidermis can be divided into 
the stratum basale, stratum spinosum, stratum 
granolusum and stratum corneum (SC). Besides 
keratinocytes also melanocytes, Langerhan’s 
cells and Merkel cells reside in the epidermis. 
The stratum basale is usually described as one-
cell-layer thick (11). In the stratum spinosum the 
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keratinocytes are enlarged and are 
interconnected by numerous desomosomal 
plaques, which interact between keratinocytes to 
form a stabilizing network of interconnections. 
Cytoskeleton filaments also attach close to 
desmosomes to provide stability across the cell 
layers. The stratum spinosum is succeeded by 
the stratum granulosum. This layer contains both 
keratohyalin granules and lamellar bodies. 
Lamellar bodies discharge lipid components into 
the intercellular space, which is important for 
barrier function. The keratohyalin granules 
contain profilaggrin, contributing to skin barrier 
homeostasis. Tight junctions are located just 
below the SC at the level of the stratum 
granulosum (12) and function as the “gate” for 
the passage of water, ions, and solutes through 
the paracellular pathway (13). The outermost 
layer is the SC where the keratinocytes (now 
called corneocytes) have lost their nucleus and 
cytoplasmic organelles. The SC consists 
consisting of multiple layers of corneocytes. 
Located within the stratum corneum, the 
cornified envelope (CE) is an insoluble protein 
matrix vital for skin-barrier function and 
integrity. It replaces the plasma membrane of the 
granular cells during cornification. The SC 
barrier is maintained by the complex interaction 
of the CE, intra-cytoplasmic moisturizing 
factors, and a complex lipid mixture in the 
extracellular space. A constant, regulated 
turnover of keratinocytes moves from the 
stratum basale, being shed in the SC. The total 
turnover time in the epidermis is thought to take 
approximately 50-75 days (14). The process of 
desquamation where the corneocytes are shed 
involves degradation by proteases of the 
laminated lipids in the intercellular spaces and 
loss of desmosomal interconnections (15).  
 
The dermis is a resilient tissue which provides 
nutrition to the epidermis as well as a supportive 
function against mechanical injury. The dermis 
contains few cells, the majority being fibroblasts 
that secrete dermal constituents. Other cells 
include mast cells, melanocytes and 
immunological cells such as macrophages and 
lymphocytes. The dermis is a matrix where 
polysaccharides and proteins are linked to 
produce macromolecules with high water 
binding capacity. Included among these proteins 
are collagen, which has great tensile strength, 
and elastin which provides elasticity. The 
polysaccharides include glucoseaminoglucans 
and hyalorinic acid. These have a major role in 
the supporting matrix of the connective tissue 
(16). 
 
1.2.2 Epidermal differentiation and 
the skin barrier 
The process of keratinization in the epidermis 
includes changes in keratins, CE proteins, 
plasma-membrane glycoproteins, intercellular 
lipids, desmosomes and other adhesion proteins. 
The process is thought to be mediated by 
calcium levels that tightly control differentiation 
and activation of genes encoding epidermal 
structural proteins (17). In the basal layers 
proteins such as keratin 5 and 14 are the main 
structural proteins. Higher up in the stratum 
spinosum, desmogleins are expressed together 
with transglutaminase 1 and 5. In the granular 
layer proteins such as filaggrin, cornulin, 
transglutaminase 1 and 3 and keratins 1 and 10 
are active; and in the SC involucrin, loricrin, 
filaggrin, small proline-rich proteins (SPRs) and 
S100A proteins are abundant. The cells are 
flattened and their keratin filaments are aligned 
under the influence of filament aggregating 
proteins (filaggrins). Filaggrin aggregates the 
keratinocyte cytoskeleton prior to being 
crosslinked with other epidermal proteins and 
lipids by epidermal transglutaminase enzymes, 
forming the CE barrier (Fig. 1). Subsequently 
filaggrin degradation products, including 
urocanic acid (UCA) and pyrrolidone carboxylic 
acid (PCA) act as natural moisturizing factors 
(NMF) and play a central role in maintaining 
hydration of the SC and affect enzyme activity, 
pH and antimicrobial defense (18, 19).  
 
 
 5 
 
 
 
Figure 1: Schematic overview of the 
structural composition of the skin barrier and 
gene expression localization in the 
epidermis. The skin is divided into the 
epidermis, dermis and the subcutis. The 
epidermis is the outermost layer and consists of 
the basal layer, the stratum spinosum, stratum 
granulosum and the stratum corneum. The 
process of keratinization takes place in the 
epidermis as the basal keratinocyte 
differentiates from the basal layer into the 
cornified stratum corneum. The cornified 
envelope within the SC is an insoluble cross 
linked protein and lipid barrier embedded in a 
lipid bilayer. Figure modified from Candi 2005 
(20) and Segre 2006 (21). 
 
1.2.3 The immune system in the skin 
The skin barrier has a mechanical, chemical, and 
immunologic component. The role of the latter is 
to elicit a powerful defense reaction in the case 
of danger and, at the same time, prevent such a 
reaction against harmless substances. Immune 
responses originating from the skin are initiated 
and executed by cells and molecules of both the 
innate and the adaptive immune system. Innate 
reactions are the first line of host defense, and 
are typically rapid, poorly discriminating, and 
lack memory. Adaptive responses, in contrast, 
show a high degree of specificity as well as 
memory but need a prolonged time for its 
development. As a consequence, innate and 
adaptive responses are parallel events 
influencing each other. In fact, the type and  
 
 
magnitude of the innate reactions often 
determine the quality and quantity of adaptive 
responses (22). 
 
The main functions of the innate immune system 
involves induction of immediate responses 
against potentially harmful microorganisms such 
as bacteria, fungi and viruses (23). Inflammatory 
responses by immune cells of the innate system 
(i.e. granulocytes and macrophages) can be 
rapidly triggered and followed by activation of 
dendritic cells and natural killer cells (24, 25). 
Resident skin cells such as keratinocytes also 
contribute to the innate immune response by 
inducing secretion of antimicrobial peptides, and 
mast-cells may provide strong pro-inflammatory 
effect when activated (26). The innate system 
engulfs and destroys pathogens, triggers pro-
inflammatory responses and helps present 
antigen by antigen presenting cells such as 
dendritic cells; subsequently priming the 
adaptive immune response (27). The 
presentation of antigen through an antigen-
presenting cell takes place on major 
histocompability complex (MHC) molecules. In 
humans, the MHC are called human leukocyte 
antigen (HLA). Dendritic cells contribute to 
initiating both primary and secondary adaptive 
immune responses, and in the skin are 
subdivided according to immunophenotype into 
Langerhans cells, inflammatory dendritic 
epidermal cells and plasmatocytoid dendritic 
cells (28). This network of dendritic cells is 
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regarded as a first barrier of the normal skin 
immune system against environment. It may 
upon antigen exposure migrate to the draining 
lymph node for antigen presentation (28). 
However, the innate system may also 
discriminate between antigens. This process is 
mediated by pathogen-associated molecular 
patterns (PAMPs) capable of showing target 
specificity towards molecules such as bacteria, 
viruses and fungi (24). In mammals the receptors 
handling PAMP recognition are called pattern 
recognition receptors (PRR). The major PRR of 
the innate immune system are toll-like receptors, 
nucleotide oligo domain-like receptors and RIG-
I-like receptors. These PRR are germ line 
encoded and are constitutively expressed by both 
immune and non-immune cells. Following 
PAMP recognition, PRR activate signaling 
pathways that may lead to more antigen-defined 
innate immune response (27). This response also 
helps prime the subsequent antigen-specific 
immune response.  
 
Adaptive immunity includes acquired but time-
delayed defense mechanisms against pathogens. 
Adaptive immune responses are mediated by T 
and B cells. B cells have specificity for a defined 
antigen that has been presented by an antigen-
presenting cell. Following exposure, clonal 
expansion of the antigen-specific B cell takes 
place. These specific B cells can bind and 
produce antibodies targeting the antigen. 
Antibodies produced by B cells may also 
activate mast-cells that upon activation release 
pro-inflammatory mediators. T cells can have 
diverse functions, and are activated in the lymph 
node after antigen exposure. They expand 
rapidly and secrete cytokines that regulate the 
following immune response. Depending on the 
cytokine milieu, the native T cell differentiates 
to Th1, Th2, Th17 or any other subgroup 
(including Cd8+ cytotoxic T cells), that in turn 
secrete specific cytokines. T cells contain highly 
diverse antigen receptors and are generated by 
DNA rearrangement events. They can recognize 
both novel and conserved antigens. This system 
requires recombination leading to different cell 
clones capable of specific protein recognition, 
instead of pattern recognition. This more 
complex immune response has as a major 
advantage that it may be built against many 
structural proteins and is able to improve its 
reactions with repeated exposure. The major 
disadvantage following this is a considerable 
risk of autoimmunity (28).  
 
1.3 ATOPIC DERMATITS 
Atopic dermatitis (AD; OMIM# 603165), is an 
inflammatory skin disorder that affects up to 20 
% of children and 3-5% of adults in the western 
world (29, 30). Diagnosis rests on clinical 
features and the U.K. working party’s criteria 
are frequently used. They are pruritus, typical 
distribution, early onset, dry skin and a personal 
or family history of atopic disease (31). During 
infancy AD affects mainly the face, scalp and 
extensor surfaces of the extremities. In older 
children and in those with persistent AD, 
lichenification develops and affected sites 
usually include the flexural folds of the 
extremities. In adults, chronic hand eczema may 
be the primary manifestation of AD but eczema 
in the head and neck region is also common 
(32). The age-dependent localization of AD 
lesional areas is still largely unknown although 
proposed predisposing factors include local 
thickness of the SC and the variation in exposure 
to exogenous substances, such as irritants and 
allergens, together with so far unknown factors 
(19).  
 
1.3.1 AD nomenclature and atopy 
AD is included among the atopic disorders, 
together with allergic asthma and allergic 
rhinoconjunctivitis. AD is frequently also 
referred to as atopic eczema, or eczema 
according to the World Allergy Organization 
(33). Atopy is defined as a personal and/or 
familial propensity to produce IgE antibodies 
and sensitization in response to environmental 
proteins (33). Although AD is strongly 
associated with a tendency to produce IgE 
antibodies, this is not always the case (34). For 
instance, the atopy prevalence in AD hospital 
surveys have been estimated to 47-75 % (34). 
The name AD is widely used in the publications 
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underlying the present work, is still the OMIM 
and medical subject headings (MESH) terms and 
is therefore used throughout, although the 
terminology is debated (35). The phenomenon of 
AD in infants often recurring with other atopic 
manifestations later in life has been referred to 
as the atopic march (36). Underlying atopy has 
been considered to be critical in linking AD, 
allergic rhinitis and allergic asthma and the 
concept of the atopic march has been supported 
by cross-sectional and longitudinal studies (37). 
Patients with AD may develop a typical 
sequence of AD and allergic asthma and rhinitis, 
which develop at certain ages. Some may persist 
for several years, whereas others may resolve 
with increasing age (38). The mechanisms of 
growing out of AD remain largely unknown and 
could be influenced by both genetic and 
environmental factors (37). Approximately 70% 
of patients with AD develop allergic asthma 
compared with 20-30% of patients with mild AD 
and approximately 8% in the general population 
(37). However, the development of atopic 
diseases is individually influenced by both 
genetic and environmental factors and they may 
still (while sharing genetic and environmental 
risk factors) develop independently from each 
other.  
 
1.3.2 AD pathogenesis 
Central in AD pathogenesis are combinations of 
acquired and inherited factors thought to alter 
the epidermal structure. These changes in the 
physiological skin barrier predispose to 
increased antigen penetration and are followed 
by immune activation, which in turn has 
negative consequences for skin barrier 
homeostasis (39). In addition to genetic disease 
mechanisms, environmental and individual 
trigger factors are important (40).  
 
Environmental trigger factors described for AD 
include food allergens such as cow’s milk and 
hen’s egg in children, and allergens such as 
house dust mites, pets and pollen in both 
children and adults (40). In addition, super-
infections are common in patients with AD, 
particularly with Staphylococcus aureus that 
colonize more than 90% of patients. This may 
aggravate skin inflammation and tissue damage 
by induction of T cell mediation by an 
superantigenic effect, by specific IgE immune 
responses against Staphylococcus aureus and 
toxins and through toll-like receptor-mediated 
immune reactivity (41). In addition other factors 
such as physiological conditions of the skin 
barrier altered by using soap and detergents on 
the skin are thought to mediate the release of 
pro-inflammatory cytokines from keratinocytes 
(19). Also, psychological factors are important, 
and psychological stress is a significant 
contributor to the disease course through direct 
and indirect effects on immune response, 
cutaneous neuropeptide expression, and skin 
barrier function by inhibition of epidermal lipid 
synthesis (42). 
 
Studies have shown that the barrier function in 
AD is altered. This barrier defect, evident e.g. 
from studies on transepidermal water loss 
(TEWL), can be seen in active lesions, where the 
inflammatory response is likely to play an 
important role, but also in non-lesional skin 
areas suggesting that the barrier defect is an 
underlying factor in AD. The impaired 
homeostasis of the skin leads to increased 
TEWL as well as changes in gene expression 
patterns (43) and enzymatic activity (44). This 
dysfunction is the result of one or more of 
several factors, and may in addition to 
environmental factors include reduced levels of 
SC lipids (45-47); acquired or genetic defects in 
key epidermal differentiation proteins such as 
filaggrin (48-51) or epidermal enzymes (49, 52, 
53) .  
 
The immune response in AD skin is 
characterized by infiltration of T cells and 
dermal dendritic cells, with distinct subsets of 
cell types including more increased Th2 
lymphocytes than Th1 and Th17, and often 
overrepresentation of increased IgE and 
eosinophil numbers in circulation (54-56). The 
defective epithelial barrier in AD is thought to 
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lead to penetration by epicutaneous antigens. 
These antigens encounter antigen-presenting 
cells such as dendritic cells that induce Th2 cells 
to produce cytokines such as Il4 and IL13. These 
cytokines in turn induce an IgE class switching 
as well as promotes Th2 cell survival. The 
cytokines produced by the increasing  
 
Figure 2: Overview of genome wide linkage 
studies of AD. 22 autosomal and sex 
chromosomes represented with candidate 
regions highlighted. Figure modified from Barnes 
2010 (57). 
 
number of Th2 cells skews the production away 
from Th1 and Th17. Also such cytokines have 
direct effects on the epidermis, by inhibiting 
terminal differentiation and production of anti- 
microbial peptides by keratinocytes, leading to 
an increasingly disrupted epidermal barrier (50, 
58) as well as predisposing to AD associated  
 
super-infection (59). However, a subset of AD 
patients have been proposed having a intrinsic 
type of AD, as opposed to extrinsic AD (60). 
They do not display increased IgE and 
eosinophil numbers in circulation, other atopic 
manifestations, and do not have a distinct Th2 
switching. Furthermore, the barrier dysfunction 
in these patients is thought be minor, and smaller 
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molecules than protein allergens may be of more 
importance for the subsequent inflammatory 
response (61). This terminology is however 
debated, and there may exist a dynamic 
relationship between these putative subtypes 
(62). 
 
1.3.3 Genetics of AD 
Pathogenesis is a complex interaction between 
environmental factors and genetic 
predisposition. The genetic predisposition has 
been indicated by high family incidence and 
concordance of 0.72-0.86 in monozygotic and 
0.21-0.23 in dizygotic twins (63, 64).  
 
Figure 3: FLG organization and location of 
described mutations. FLG is composed of a 
large transcript encoded by three exons, of 
which the third encodes the FLG repeats. The 
majority of the FLG sequence consists of 
repeating 35 kiloDalton units separated by a 
short amino-acid linker peptide (A). Prevalent  
 
Previous genome-wide linkage screens of AD 
(65-70) (Fig. 2) have reported suggested linkage 
and other chromosomal regions such as on 
chromosome 14 (71) has been associated to AD. 
The European AD GWAS published to-date has 
confirmed 1q21 as a major susceptibility locus 
(72) as well as an open reading frame on 
chromosome 11 (C11orf30); and recent 
replication have indicated that the C11orf30 
locus may have an epistatic effect with the 
strong association to filaggrin (FLG) on 
chromosome 1q21 (73).  
 
 
 
mutations are marked in red, family specific in 
black, and the novel mutation 623del2 detected 
in paper I in blue (here also termed 1869del2). 
FLG has a variable number of repeats, 
consisting of 10, 11 or 12 units (B). Recurrent 
mutations can occur in the 10, 11 or 12-repeat 
allele. Picture modified from O’Regan 2009 (74). 
UTR= Untranslated region. 
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The epidermal differentiation complex (EDC) on 
chromosome 1q21 has been mapped in previous 
genome-wide linkage studies (57) as well as in 
GWAS (72) as a susceptibility region for both 
AD and psoriasis (66, 75). The EDC contains a 
cluster of genes of importance for terminal 
differentiation of keratinocytes and subsequently 
for skin barrier function and integrity (76). EDC 
proteins share significant sequence similarities, 
and phylogenetic association suggests that these 
proteins are derived from a common ancestor, 
evolving to meet tissue-specific demands (74, 
77). In the EDC lies the FLG gene, encoding 
filaggrin. In 2006, loss-of-function variants in 
the FLG gene were identified in patients of 
Scottish, Irish and European-American descent, 
as the causative genetic factor in the most 
common form of ichthyosis, ichthyosis vulgaris 
(IV; Online Mendelian Inheritance in Man 
#146700) (78). There were indications that AD 
patients had decreased expression of filaggrin in 
the skin (79) and there is a clinical overlap 
between IV and AD. When tested, the FLG 
variants were strongly associated with AD in an 
Irish AD cohort (48). This is so far the most 
significant genetic finding associated with AD 
(51), and it is estimated that 42% of all FLG 
mutations carriers develop AD (80). It has been 
shown that FLG mutations are population-
specific and a difference in the spectra of 
mutations has been described. At present, more 
than 40 loss-of-function mutations have been 
reported in European and Asian populations 
(81).  
 
FLG mutations are the major determinants of the 
levels of the filaggrin breakdown products 
contributing to the NMF, such as pyrrolidone 
carboxylic acid and urocanic acid (19). 
However, filaggrin deficiency may also lead to a 
disturbed epithelial differentiation and prone to 
skin inflammation (80). The integrity of the 
stratum corneum is maintained primarily by 
extracellular lipid lamellae (82). Filaggrin 
deficiency may contribute to defective lipid 
lamellae through several mechanisms. By 
impaired keratin intermediate filament (KIF) 
aggregation in the SC, the maturation and 
excretion of extracellular lamellar bodies is 
disturbed (83). Further, tight junctions that seal 
epidermal cell-cell integrity seem to be reduced 
in number in filaggrin-deficient individuals, 
together with a decreased density of 
corneodesmosin, which is the major component 
of corneodesmosomes (critical for SC cell-to-
cell adhesion) (12, 83).  
 
Filaggrin breakdown products are acidic, and 
elevated skin-surface pH observed in filaggrin–
deficient individuals (84) may be important as 
the effect of several epidermal serine proteases 
depends on pH. A more neutral or alkaline pH 
may activate kallikrein serine proteases with 
major downstream consequences, including 
blockade of lamellar-body secretion (85). 
Activation of serine proteases may also drive 
Th2-inflammation even in the absence of 
allergen priming (86). It has also recently been 
shown that variation in intragenic copy number 
of FLG repeats (Fig. 3) contributes to a dose 
dependent reduction in AD risk independent of 
mutations; with an OR of 0.88 for each 
additional repeat compared to the 10 repeat 
allele (87). 
 
Experimental evidence for the hypothesis that 
antigens enter through an impaired epidermal 
barrier inducing systemic allergen-specific IgE 
responses is supported in a mice with filaggrin 
frame shift mutation, analogous to human 
filaggrin mutation. Epicutaneous application of 
allergen to these mice resulted in cutaneous 
inflammatory infiltrates and enhanced cutaneous 
allergen priming with development of IgE 
antibody responses (88). 
 
The genetic association with genes involved in 
the skin barrier homeostasis, such as FLG (48) 
and protease activity (89, 90) and immune 
response genes demonstrate the molecular 
background to AD is complex. Various clusters 
of genes are altered, including inflammatory and 
epidermal differentiation genes (43). Table 1 
lists selected genes that have been associated 
with AD in at least two studies. These genes 
include functions in the adaptive and innate 
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immune response as well as proteins involved in 
the terminal differentiation (54).  
 
1.4 ICHTHYOSIS 
The ichthyoses form a large, clinically and 
etiologically heterogeneous group of 
cornification disorders that typically affect all or 
most of the skin surface (91). There are at least 
six distinct clinical subtypes that belong to the 
hereditary non-syndromic ichthyoses; harlequin 
ichthyosis (OMIM#242500); lamellar ichthyosis 
(OMIM#242300); congenital icthyosiform 
erytrodermia (OMIM#242100); epidermolytic 
(OMIM#113800) and superficial epidermolytic 
ichthyosis (OMIM#146800); recessive x-linked 
ichthyosis (XLI; OMIM#242100) and the 
mildest most common form; IV (92). IV affects 
1:250 to 1:400 and 37-50% of these patients also 
have atopic manifestations (78). Central for the 
ichthyoses are disturbed pathways related to the 
intercellular lipid layer, cornified cell envelope 
formation or function of the keratin network; all 
leading to a subsequent disturbed skin barrier 
(92). 
 
1.4.1 Genetics of ichthyosis 
The known causative genes underlying common 
ichthyoses include ABCA12, ALOXE3, 
ALOX12B, FLJ39501, NIPAL4, FLG and STS. 
ABCA12 encodes a known keratinocyte lipid 
transporter associated with lipid transport in 
lamellar granules, and a loss of ABCA12 
function leads to defective lipid transport in the 
keratinocytes, resulting in the severe harlequin 
ichthyosis phenotype. Other causative genes for 
ichthyoses are transglutaminase 1 (TGM1), 
keratin 1, 10 and 2 and steroid sulfatase (STS). 
TGM1 encodes an enzyme with a role in 
cornified cell envelope formation and mutations 
are causative for lamellar ichthyosis (93). 
Keratin 1, 10 and 2 encodes proteins involved in 
the keratin network of suprabasal keratinocytes, 
and mutations are causative of epidermolytic 
ichthyosis and superficial epidermolytic 
ichthyosis, respectively. XLI in turn is caused by 
partial or complete deletions or inactivating 
mutations in the STS gene leading to deficient 
STS activity. STS degrades cholesterol sulfate in 
the intercellular spaces of the SC, and deficiency 
leads to both malformation of the intercellular 
lipid layer and a delay in corneodesomsome 
degradation, resulting in abnormal desquamation 
(94). Finally, it was found in 2006 that 
mutations in the FLG gene resulting in filaggrin 
dysfunction are the causative genetic factor for 
IV (78). Table 1 lists genes associated with 
distinct subtypes of common ichthyoses. 
 
1.4.2 Ichthyosis and AD 
It is well established that IV is commonly 
associated with atopic manifestations in 37-50% 
of cases (78), and that the genetic underlying 
factor causing IV, FLG mutations, is strongly 
associated to AD (48). It has been widely 
replicated that 20-40% of European and Asian 
patients with moderate-to-severe AD carry FLG 
mutations. However, all carriers do not manifest 
AD or IV and roughly 7-10% of the general 
European population (95) carry at least one FLG 
loss-of-function allele, regardless of symptoms. 
FLG mutations may also modify the course in 
XLI (96, 97). However, no association has been 
described regarding atopic manifestations and 
XLI or other rare forms of ichthyosis, although 
impairment in pathways important for skin 
barrier function are, like in AD, evident in these 
conditions.  
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Table 1: List of selected replicated genes 
associated to AD, psoriasis or ichthyosis. 
Table modified from Guttman-Yaski et al (122), 
Akiyama et al (92) and Barnes (57). All gene 
names are abbreviated followed by reference to 
initial association study. 
Atopic Dermatitis Chr.    
region 
Psoriasis Chr. 
region 
Ichthyosis Chr. 
region 
ADAPTIVE IMMUNE RESPONSE GENES  
  
Interleukin 4/13 (IL4/13) (98, 99) 5q31 Interleukin 4/13 (IL4/13) 
(100) 
5q31   
Interleukin 4 RA (IL4RA) (101) 5p13 Human leukocyte 
antigen-C/Psoriasis 
susceptibility 1 (HLA-
C/PSORS1) (102, 103) 
6P21.3   
Mast cell chymase 1 (CMA1) (104) 14q11.2 Interleukin 23R (IL23R) 
(100, 103) 
1p31.3   
Interleukin 18 (IL18) (105) 11q22.2-
q22.3 
Interleukin 23A (IL23A) 
(100, 103) 
12q13.3   
RANTES (106) 17q11.2-q12 Interleukin 12B (IL12B) 
(107) 
5q33.3   
 
INNATE IMMUNE RESPONSE GENES 
  
Nuclear-binding oligo-domain 1 (NOD1) 
(108) 
7p15-p14 Tumor necrosis factor 
AIP3 (TNFAIP3) (100, 
103) 
6p23   
Toll-like receptor 2 (TLR2) (109) 4q32 Tumor necrosis factor 
AIP3 interacting protein 
1 (TNIP1) (100, 103) 
5q33.1   
Cluster of differentiation antigen 14 
(CD14) (110) 
5q31.1     
Defensin β1 (DEFB1) (111) 8p23.1     
Glutathione S-transferase pi 1 (GSTP1) 
(112) 
11q13     
 
TERMINAL DIFFERENTIATION AND BARRIER GENES 
 
Serine peptidase inhibitor, Kazal-type 5 
(SPINK-5) (113) 
5q32 Late cornified envelope 
3B (LCE3B) (114) 
1q21.3   
C11orf30 (72)  Late cornified envelope 
3C (LCE3C) (114) 
1q21.3   
Filaggrin (FLG) (48) 1q21.3   Filaggrin (FLG) 
(78) 
1q21.3 
    Transglutaminase 
1 (TGM1) (93) 
14q11.2 
KERATIN NETWORK GENES   
    Keratin 1 (KRT1) 
(115) 
12q12-13 
    Keratin 2 (KRT2) 
(116) 
12q11-
q13 
    Keratin 10 
(KRT10) (115) 
17q21 
 
INTERCELLULAR LIPID ORGANISATION GENES 
   
    ALOXE3 (117) 17p13.1 
    ALOX12B (117) 17p13.1 
    ABCA12 (118) 2q34 
    CYP4F22 (119) 19p12 
    NIPAL4 (120) 5q33 
    Steroid sulfatase 
(STS) (121) 
Xp22.32 
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1.5 PSORIASIS 
Psoriasis (OMIM#177900) is an heterogeneous 
disease that affects roughly 2% of the adult 
population (123) with 0.5 % having onset before 
15 years of age (124). It is characterized by 
inflammation of the skin and sometimes joints 
(psoriatic arthritis) (125). The disease varies in 
severity depending on both inheritance and 
environmental factors. Some patients may 
manifest mild disease with isolated scaling 
erythematous plaques on the elbows, knees, or 
scalp, whereas in others almost the entire 
cutaneous surface is affected (123). The most 
common form of psoriasis, plaque psoriasis, 
occurs in more than 80% of affected patients. 
Other sub-types include inverse psoriasis and 
guttate psoriasis (123). Although psoriasis is 
characterized by proliferation of the epidermis, 
the immune system has a prominent role in 
development of this disease, and psoriasis 
patients have in addition increased risk of 
acquiring comorbidities such as ischemic heart 
disease, hypertension, type 2 diabetes mellitus 
and obesity (125). 
 
1.5.1 Genetics of psoriasis 
There is a strong genetic background underlying 
psoriasis pathogenesis with strong association to 
pathways involving antigen-presentation such as 
the HLA-C complex and ERAP1 (103) gene. T 
cell signaling and NFKB-pathway activation are 
also associated with manifestation of the disease 
(126), and a disturbed interplay between T cells 
is thought to be a key feature underlying the 
pathogenesis (127). Recently, it has been shown 
that deletions in genes important for epidermal 
protein expression are also associated with 
psoriasis (128). This indicates that like AD, 
psoriasis display a complex interplay between 
epidermal barrier function and immunological 
response. Table 1 lists commonly replicated 
genes associated with psoriasis. 
 
 
1.5.2 Psoriasis and AD 
AD and psoriasis are two of the most common 
inflammatory skin disorders and are genetically 
complex, multifactorial, and do not follow a 
Mendelian pattern of inheritance (59). 
Concomitant manifestation of psoriasis and AD 
is thought to be rare (129). The epidermal 
differentiation complex (EDC) region on 
chromosome 1q21 has been highlighted as a 
susceptibility locus for both AD and psoriasis 
(130). The EDC genes encode proteins in the 
uppermost layers of epidermis vital for 
keratinocyte differentiation and barrier integrity 
(131). This locus has previously been identified 
and named as PSORS4 (132), and it has been 
replicated that polymorphisms in the EDC genes 
LCE3B and LCE3C (late cornified envelope 3B 
and 3C) influence psoriasis susceptibility (128) 
although no association has been shown with 
AD (131). However, altogether abnormalities in 
epidermal protein expression seem important for 
the pathogenesis in both AD and psoriasis. 
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2 AIMS OF THE PRESENT 
WORK  
 
The overall aim was to improve our 
understanding of the genetic mechanisms 
underlying skin barrier defects with the main 
focus on AD. Specific aims were: 
 
 to further explore the spectrum of FLG 
mutations in different populations as a 
genetic susceptibility factor underlying 
AD and IV by studying the role of FLG 
mutations in an Ethiopian case control 
material. 
 
 to investigate whether mutations in the 
FLG gene may impact childhood onset 
of psoriasis. 
 
 to study whether the functional and 
molecular alterations in AD and IV skin 
are dependent on filaggrin deficiency, 
and whether FLG genotype determines 
the type of downstream molecular 
pathways affected.  
 
 to test whether genetic variability at the 
epidermal transglutaminase gene loci 
may contribute to AD susceptibility, and 
if alterations in transglutaminase gene 
expression is linked to manifestation of 
the disease. 
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3 MATERIAL AND 
METHODS 
 
3.1 CLINICAL MATERIAL 
A Swedish AD family material, an Ethiopian 
AD case control material, a Swedish ichthyosis 
material and a Swedish psoriasis case control 
material have been used in the papers included 
in this work.  
 
An Ethiopian case control material was included 
in paper I and consists of patients with AD 
and/or IV (cases; n=110) and subjects without 
past or present history of AD, dry skin or atopic 
manifestations (controls; n=103). This was done 
in collaboration with the Skin Department at 
Black Lion University Hospital in Addis Ababa, 
Ethiopia. All patients had been diagnosed with 
AD by a dermatologist, based on clinical 
examination and according to the UK Working 
Party’s diagnostic criteria (31). The IV diagnosis 
was based on clinical examination. Genetic 
testing was performed of the STS gene to 
exclude X-linked recessive ichthyosis. All 
individuals included were interviewed using a 
standardized questionnaire regarding atopic 
manifestations. Age of onset of AD, food allergy 
(past or present), urticaria, allergic asthma or 
rhinoconjunctivitis were all assessed through the 
questionnaire together with family history of 
atopy. In addition, there is detailed information 
available from 53 AD patients regarding 
associated phenotypes and both total serum IgE-
levels as well as allergen-specific serum IgE-
levels.  
 
Total serum IgE and allergen-specific serum IgE 
against Dermatophagoides pteronyssinus, hen’s 
egg, and mold mix (Mx2) including Penicillium 
notatum, Cladosporium herbarum, Aspergillus 
fumigatus, Candida albicans, Alternaria 
alternate and Helminthosporium halodes were 
measured using the ImmunoCAP method 
(Phadia AB, Uppsala, Sweden). Cutoffs for 
raised total serum IgE was 22.3 kU/L (9 monts-5 
years), 263 kU/L (5-20 years) and 122 kU/L 
(>20 years). For allergen-specific serum IgE, 
concentrations below 35 kU/L were considered a 
negative result. Phenotype data can be found in 
Table 2. 
 
 
Table 2: Phenotypes of AD patients, IV 
patients and healthy controls from an 
Ethiopian AD case-control material. 
 
Phenotype of Ethiopian AD patients (n=103) % 
Female sex 43.6 
Age (median; range) 7.0;0.3-
34.0 
Family history of atopy (asthma, AD or allergic 
rhinoconjunctivitis) 
49.5 
Personal history of asthma or allergic 
rhinoconjunctivitis 
27.1 
Early age of onset (<2 years) 65 
Keratosis pilaris / palmar hyperlinearity 15.5 
Xerosis 99 
Mild AD (SCORAD <15) 2 
Moderate AD (SCORAD 15-40) 65 
Severe AD (SCORAD >40) 33 
  
Phenotype of Ethiopian IV patients (n=7) % 
Female sex 42.8 
Age (median; range) 11.0; 0.7-
65.0 
U.K. working party's criteria for AD 16.7 
Family history of atopy (asthma, AD or allergic 
rhinoconjunctivitis) 
28.6 
Personal history of asthma or allergic 
rhinoconjunctivitis 
0 
Keratosis pilaris / palmar hyperlinearity 100 
Xerosis 100 
Phenotype of Ethiopian healthy controls 
(n=103) 
% 
Female sex 53.4 
Age (median; range) 9.0; 0.7-
60.0 
U.K. working party's criteria for AD criteria 0 
Family history of atopy (asthma, AD or allergic 
rhinoconjunctivitis) 
0 
Personal history of asthma or allergic 
rhinoconjunctivitis 
0 
Keratosis pilaris / palmar hyperlinearity 0 
Xerosis 0 
 
Among AD patients where serum was avaliable, 
26/53 (49%) showed elevated total serum IgE 
(median 120 kU/L; inter-quartile range 44–540). 
Of the allergen-specific serum IgE, 6/53 (11%) 
patients had elevated levels against hen’s egg 
(all aged 0–5 years), 6/53 (11%) against mould 
mix and 12/53 (23%) against Dermatophagoides 
pteronyssinus. Patients with severe AD had 
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significantly higher total serum IgE (p-
value= 0.012) and higher allergen-specific 
serum IgE levels against Dermatophagoides 
pteronyssinus (31%) than patients with mild to 
moderate AD (20%), although this did not reach 
statistical significance (p-value= 0.32). Age and 
gender distribution were similar in the mild to 
moderate and severe AD subgroups. Allergen-
specific serum IgE levels in patients with mild to 
moderate and severe AD are summarized in 
Table 3. 
 
Table 3: Total and allergen-specific serum 
IgE levels for patients with AD.  
Total and allergen specific IgE-
levels 
Mild to 
moderate 
AD  
Severe 
AD  
Number of individuals 40 13 
Total serum IgE (kU/L) 
(median± SD) 
78±810 400±1350 
Elevated total serum IgE (>100 
kU/L) (%) 
41 76.9 
Serum egg IgE positive (>0.35 
kU/L) (%) 
10.3 15.5 
Serum Der p
1
. IgE positive (>0.35 
kU/L) (%) 
20.0 30.8 
Serum mold mix positive (>0.35 
kU/L) (%) 
10.0 15.5 
1
Der p, Dermatophagoides pteronyssinus. 
 
In paper II, a patient with clinical signs of 
ichthyosis was analyzed. The patient was male 
and 73 years old. He displayed dry, gray-brown 
scales especially prominent on the legs and the 
extensor surfaces of the arms, without flexural 
involvement or involvement of the soles or 
palms. He was adopted as a baby, and he has 
been told that his biological father had dry skin 
in the flexural areas; otherwise there was no 
knowledge about any family history of skin 
manifestations or atopy.  
 
A Swedish psoriasis case control material was 
used in study III consisting of 241 children with 
onset of psoriasis below 15 years of age and of 
314 healthy controls. They were identified at the 
Dermatology Department, Karolinska University 
Hospital, Solna, Sweden, and diagnosed by the 
same dermatologist. Blood samples were taken 
and medical history was recorded using a 
standardized questionnaire. Psoriasis severity 
was assessed with the Psoriasis Area and 
Severity Index (PASI) (133) and graded with an 
arbitrary disease severity score (1-7).  
 
Patients from a Swedish AD family material 
were analyzed in paper IV and V. They were 
recruited during 1995-1997 at the Dermatology 
Departments of the Karolinska Solna and 
Danderyd Hospital, Sweden. Families with at 
least two affected siblings were included, 
resulting in 539 nuclear families from a total of 
1753 individuals. All the siblings were 
diagnosed with AD by the same dermatologist, 
based on clinical examination and according to 
the UK Working Party’s diagnostic criteria (31). 
All siblings were interviewed using a 
standardized questionnaire regarding atopic 
manifestations. Age of onset of AD, food allergy 
(past or present), urticaria, allergic asthma or 
rhinoconjunctivitis were all assessed through the 
questionnaire together with any family history of 
atopy. In addition, detailed individual 
information is available on AD severity (Table 
4), associated phenotypes, total serum IgE-levels 
and allergen-specific serum IgE-levels. Total 
serum IgE and allergen-specific serum IgE were 
measured using the Pharmacia CAP System IgE 
FEIA (Pharmacia & Upjohn Diagnostics AB, 
Uppsala Sweden). Cutoffs for raised total serum 
IgE was 22.3 kU/L (9 monts-5 years), 263 kU/L 
(5-20 years) and 122 kU/L (>20 years). 
Allergen-specific serum IgE antibodies were 
analyzed against house dust mite 
(Dermatophagoides pteronyssinus and 
Dermatophagoides farinae), cat, dog, horse, 
birch, timothy grass, mugwort, olive, 
Cladosporium herbarum and/or Parietaria 
judaica and food mix (including hen’s egg 
white, cow’s milk, soya bean, peanut, fish and 
wheat flour). For phenotype data of included AD 
siblings see Table 5. 
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Table 4: Arbitrary assessment of AD severity. 
Each factor yields a score of 1-2, with a 
combined maximum score of 5. Presence of AD 
in one or both sides in bilateral structures was 
considered as one site. 
Factor Score 
Age at onset <2 years 1 
Hospitalization for AD 1 
Affected sites on examination  
0 0 
0 - 3 1 
>3 2 
Raised total and/or allergen-specific IgE 1 
Maximum Score 5 
 
Table 5: Phenotype of included AD siblings 
from a Swedish AD family material. 
Phenotype of Swedish AD siblings (n=1097) % 
Female sex 65 
Age (median;range) 29; 4-65 
U.K. Working Party's criteria for AD criteria 100 
Early onset 78 
Elevated total and/or allergen-specific serum IgE 74 
Severe atopic dermatitis 15 
Personal history of AD and asthma 39 
Personal history of AD and rhinoconjunctivitis 66 
 
For paper IV; patients (n=43) with AD (n=35), 
AD and IV (n=5) and IV (n=3) together with 
controls (n=15; subjects without past or present 
history of AD, dry skin or other atopic 
manifestations) were identified at the 
Dermatology Outpatient Clinics at Karolinska 
University Hospital Solna, Sweden; 
Sophiahemmet Stockholm, Sweden and Uppsala 
University Hospital, Uppsala, Sweden; or 
recruited from a Swedish family material with 
known FLG genotype as described previously 
(134) and used in paper V. All patients were 
investigated by a dermatologist performing 
clinical examination and recording medical 
history with a standardized questionnaire. 
Inclusion criteria were age between 18-65 years 
and diagnosed AD and/or IV. Exclusion criteria 
were pregnancy; other concomitant skin disease; 
recent UV-treatment; or recent use of topical or 
systemic glucocorticoids, immunosuppressives 
or retinoids (< 4 weeks). AD was diagnosed 
according to the UK Working Party’s diagnostic 
criteria, severity being assessed using the 
scoring atopic dermatitis index (SCORAD) 
(135). IV was diagnosed by clinical examination 
and genetic testing of the FLG gene. In male 
patients with ichthyosis genetic testing of the 
STS gene was performed to rule out XLI. Other 
atopic manifestations such as allergic asthma 
and allergic rhinoconjunctivitis were assessed 
through the questionnaire. Blood samples and 
punch biopsies were taken from both patients 
and controls. Two 3 mm punch biopsies were 
obtained from a non-lesional area on each 
patient’s forearm. TEWL was assessed using a 
Tewameter TM 300 Multi Probe Adapter 
(Courage + Khazaka electronic GmbH, Köln, 
Germany) and skin pH was measured using a 
skin-pH-Meter PH 905 Multi Probe Adapter 
(Courage + Khazaka electronic GmbH). TEWL 
and pH were measured from the forearms of 
patients and controls. The patients were divided 
into three groups (AD FLG +/+; AD FLG +/- 
and AD/IV FLG -/-) depending on genotype of 
the European FLG-mutations R501X, 2282del4, 
S3247X and R2447X (136). Phenotype 
characteristics of each patient group can be 
found in Table 6. The control group contained 
43% females and the average age was 52 years 
(range 24-75 years).  
 
Table 6: Phenotype of included AD/IV 
patients from a Swedish AD and IV material. 
The AD FLG +/+ group consisted of 14 patients, 
the AD FLG +/- of 14 patients and the AD FLG -
/- of 15 patients, respectively.  
 
Phenotype of 
Swedish AD/IV 
patients 
AD FLG   
+/+ (n= 14) 
AD FLG 
+/- (n=14) 
AD FLG   
-/-  (n=15) 
Female sex (%) 78.6 64.3 46.7 
Age (median; 
range) 
56 (28-78) 54 (28-71) 59 (44-
70) 
SCORAD
1
 (median; 
range) 
7.6 (0-14.7) 15.4 (6.2-
25.8) 
14.1 (7-
44.5)
 
 
    
1 
SCORAD of patients with AD. 
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3.2 GENOTYPING 
Genotyping is the process of determining the 
genes (genotype) of an individual by examining 
the individual's DNA sequence on the basis of 
biological assays. This can be done in several 
ways. For papers included in this work, DNA 
sequencing, allelic discrimination and MLPA 
were used.  
 
3.2.1 DNA sequencing 
DNA sequencing is a method to detect sequence 
alterations and was used in papers I-V. The 
principle of Sanger sequencing includes 
denaturing and hybridizing a double stranded 
amplified PCR product using target primers, 
DNA polymerase and fluorescence-labeled 
dideoxynucleotides in addition to the normal 
nucleotides found in DNA. Dideoxynucleotides 
contain a hydrogen group on the 3’ carbon 
instead of a hydroxyl group. These modified 
nucleotides, when integrated into a sequence, 
prevent the addition of further nucleotides, as a 
phosphodiester bond cannot form between the 
dideoxynucleotide and the next nucleotide to be 
integrated. This terminates the DNA chain. Size 
separation of the DNA strands is performed with 
capillary electrophoresis and fluorescence is 
detected with a charge-colored device-camera in 
an automatic DNA sequencer. The differently 
labeled nucleotides are presented as peaks of 
different colors in generated chromatograms, 
and can subsequently be compared to a reference 
sequence. 
 
3.2.2 Allelic discrimination 
Allelic discrimination was used in papers I-V, 
and is a method that using forward and reverse 
PCR primers to amplify a region that includes an 
SNP polymorphic site. Allele discrimination is 
achieved using fluorescence resonance energy 
transfer (FRET) combined with one or two 
allele-specific probes that hybridize to the SNP 
site. The probes will have a fluorophore linked 
to their 5’ end and a quencher molecule linked to 
their 3’ end. While the probe is intact, the 
quencher will remain in close proximity to the 
fluorophore, eliminating the fluorophore’s 
signal. During the PCR amplification step, if the 
allele-specific probe is perfectly complementary 
to the SNP allele, it will bind to the target DNA 
strand and then get degraded by 5’-nuclease 
activity of the Taq polymerase as it extends the 
DNA from the PCR primers. The degradation of 
the probe results in the separation of the 
fluorophore from the quencher molecule, 
generating a detectable signal. If the allele-
specific probe is not perfectly complementary, it 
will have a lower melting temperature and not 
bind as efficiently. This prevents the nuclease 
from acting on the probe (137). 
 
3.2.3 Multiplex ligand-dependent 
probe amplification 
MLPA (Multiplex Ligation-dependent Probe 
Amplification) was used in paper I, II and IV 
and is a multiplex PCR method to detect 
abnormal copy numbers of genomic DNA or 
RNA sequences, by distinguishing sequences 
differing in nucleotides (138). In MLPA the two 
nucleotide half-probes hybridize with the 
adjacent target DNA sequence permitting 
ligation between the half-probes and creating 
one whole probe. The MLPA half-probes are 
designed so each ligation product has a unique 
size between 87 and 130 nucleotides. Ligation 
products are amplified in a subsequent PCR 
amplification and by using fluorescently labeled 
primers the PCR-product can be separated and 
measured by capillary electrophoresis. 
Comparison of the relative peak area of each 
amplification product to a normal control 
reflects the relative copy number of the target 
sequence. 
 
3.3 GENE EXPRESSION ANALYSIS 
Gene expression is the term used to describe the 
transcription of information contained within 
DNA into mRNA molecules that are translated 
into proteins. Gene expression is a highly 
complex and tightly regulated process that 
allows a cell to respond dynamically both to 
environmental stimuli and to its own changing 
needs. This mechanism acts as a switch to 
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control which genes are expressed in a cell and 
also as a gradient that increases or decreases the 
level of expression of particular genes as 
necessary. Prior to determining expression of a 
gene, most methods require conversion of 
mRNA into complementary DNA (cDNA).  
 
There are several methods of synthezing cDNA. 
Briefly, the principle of cDNA synthesis 
includes generation of complementary DNA 
from a single strand of mRNA based of the 
pairing of RNA base pairs (A;U;G;C) to their 
DNA complements (T;A;C;G). Using mature 
mRNA; two sets of primers may be used in 
parallel: a poly-A oligonucleotide primer is 
hybridized onto the poly-A tail of the  mRNA 
template, and in a separate reaction random 
hexamer primers may be hybridized, capable of 
hybridizing anywhere on the RNA. 
Subsequently, reverse transcriptase is added 
along with deoxynucleotide trisphosphates. This 
generates a complementary strand of DNA 
hybridized to the original mRNA strand. The 
RNA is digested using an RNAse; leaving a 
single stranded DNA. A DNA polymerase can 
subsequently transcribe a complementary 
sequence, generated a double stranded cDNA 
with corresponding sequence to the mRNA 
strand of interest.  
 
3.3.1 Microarray expression analysis 
A way to determine at what level a certain gene 
is expressed is microarray expression analysis. 
For paper IV, Human Gene 1.0 ST Array 
GeneChip (Affymetrix Inc, Santa Clara, CA) 
was used to hybridize cDNA derived from the 
mRNA of normal and patient samples. 
Microarrays contain immobilized DNA 
segments corresponding to regions of the 
genome, and differently fluorescent labeled test 
and reference cDNA are competitively 
hybridized to these segments. The test and 
reference cDNA are labeled and mixed prior to 
being hybridized on the existing probes on the 
array. Subsequently the array is washed before 
the array is loaded into scanning software 
measuring the ratio of the generated signal 
(Command Console Software, Affymetrix Inc).  
 
3.3.2 Real-time quantitative PCR 
Real-time polymerase chain reaction, also called 
quantitative real time polymerase chain reaction 
(qPCR), was used in papers IV-V. It is a PCR 
based method used to amplify and 
simultaneously quantify a targeted DNA 
molecule. The quantity can be either an absolute 
number of copies or a relative amount. Relative 
quantification is based on internal reference 
genes to determine fold-differences in 
expression of the target gene and is the method 
used for paper IV-V. Absolute quantification 
gives the exact number of target DNA molecules 
by comparison with DNA standards. The general 
principle of DNA quantification by real-time 
PCR relies on plotting fluorescence against the 
number of cycles on a logarithmic scale. A 
threshold for detection of DNA-based 
fluorescence is set slightly above background. 
The number of cycles at which the fluorescence 
exceeds the threshold is called the cycle 
threshold, Ct. During the exponential 
amplification phase, the sequence of the DNA 
target doubles every cycle; for instance a DNA 
sample who’s Ct reaches the threshold compared 
to another sample by 3 cycles contained 2
3
 = 8 
times more template. To quantify gene 
expression, the Ct from the gene of interest is 
divided by Ct from a housekeeping gene in the 
same sample to normalize for variation in the 
amount and quality between different samples. 
This normalization procedure is commonly 
called the ΔΔCt-method and permits comparison 
of expression of a gene of interest among 
different samples. However, for such 
comparison, expression of the normalizing 
reference gene needs to be very similar across all 
the samples. For paper IV the genes E4A, 18S, 
and GAPDH were used as endogenous controls 
as they all displayed relative stability and low 
variability across the samples run on the array. 
For paper V; 18S was used as endogenous 
control. 
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3.3.3 Immunohistochemical analysis 
Immunohistochemistry (IHC) was used in 
papers I and V and refers to the process of 
detecting antigens (e.g. proteins) in cells of a 
tissue section using the principle of antibodies 
binding specifically to antigens in biological 
tissues. The term IHC is derived from "immuno" 
in reference to antibodies used in the procedure, 
and "histo" meaning tissue. IHC is commonly 
used to understand the distribution and 
localization of markers and differentially 
expressed proteins in different tissues. An 
antibody-antigen interaction can be visualized in 
a number of ways. Commonly, an antibody is 
conjugated to an enzyme, such as peroxidase, 
that can catalyze a colour-producing reaction. 
Alternatively, the antibody can also be tagged to 
a fluorophore. 
 
 
3.4 DATA AND STATISTICAL 
ANALYSIS 
Relationships between allele and genotype 
frequencies in each analyzed SNP were tested in 
paper III-V in accordance with Hardy and 
Weinberg. If the observed and predicted 
frequency differs, a deviation from the Hardy 
Weinberg equilibrium (HWE) is said to exist. A 
deviation in HWE may indicate technical 
problems with the assay. HWE was tested using 
a chi-square test as implemented in the 
Haploview 4.1 program (139).  
 
In paper I; differences in total serum-IgE and 
allergen-specific serum IgE-levels were 
compared between mild to moderate and severe 
AD using the Mann-Whitney U test, and p-
values below 0.05 were considered statistically 
significant. The Mann-Whitney U test is a non-
parametric statistical hypothesis test for 
assessing whether one of two samples of 
independent observations tends to have larger 
values than the other when a normal distribution 
cannot be assumed. 
.  
For paper III, the significance of allele 
frequencies was calculated using Fisher’s exact 
test and the significance of difference in disease 
severity and age of onset was calculated using 
student’s t-test. P-values below 0.05 were 
considered statistically significant. Fisher’s 
exact test is a statistical significance test used in 
the analysis of contingency tables where sample 
sizes are small. The test is useful for categorical 
data. A t-test is a test commonly applied when a 
normal distribution is expected. When the value 
of the scaling term of the normal distribution is 
unknown, and estimated based on the data the 
test statistic follows a student’s t distribution.  
 
For paper IV a two-way analysis of variance 
(ANOVA) was performed to identify 
differentially expressed genes between the 
different experimental groups in the microarray 
analysis using the Partek Genomics Suite 6.4. 
ANOVA is a generalized t-test useful for 
comparing distribution of more than two groups. 
For each comparison between two experimental 
groups the fold change of every annotated gene, 
together with their corresponding p-value, was 
exported to Microsoft Office Excel. For qPCR, 
the relative mRNA expression and statistical 
significance were calculated using the REST 
2009 software (available at www.qiagen.com) 
using Fisher’s exact test. For genes chosen for 
pathway analysis, significance was corrected 
with Bonferroni multiple testing. Bonferroni 
correction is a method used to counteract the 
problem of errors generated when doing multiple 
comparisons. Briefly, it is based on the idea that 
if “n” hypotheses are tested on a set of data, one 
way to maintain statistical significance is to 
estimate that significance is maintained by 
calculating 1/”n” times what it would be if only 
one hypothesis were tested. Statistical 
significance for SCORAD was calculated using 
student’s t -test. Gene mapping to pathways was 
performed using DAVID bioinformatics 
resources (140) with the KEGG pathway 
analysis option. Gene pathway analysis was also 
performed using Ingenuity Pathway Analysis.  
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In paper V the pedigree disequilibrium test 
(PDT) and odds ratio (OR) were performed 
using the Unphased (3.1.3) program (141). 
Transmission disequilibrium test (TDT) is a 
family-based association test for the presence of 
genetic linkage between a genetic marker and a 
trait. PDT is a modified test of family linkage 
that can use all potentially informative data from 
a pedigree, even from extended pedigrees. OR is 
a common measurement of effect size. The OR 
for minor alleles was estimated relative to the 
major allele and the OR for haplotypes relative 
to all the other haplotypes in the same block 
together. For the haplotype analysis the specific 
test haplotype option was used with a rare 
haplotype frequency maximum of 2%, a zero 
haplotype frequency maximum of 1% and the 
estimate missing genotypes option. Associations 
with significant p-values were corrected for 
multiple testing by performing 10000 
permutations in the Unphased program. LD 
between polymorphisms in studied regions was 
calculated using the Haploview program.  
 
Statistical power for studies III and V was 
estimated using the Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/; 
Harvard Medical School). The power of a 
statistical test is the probability that the test will 
reject the null hypothesis when the hypothesis is 
actually false (false negative). Power analysis 
can be used to calculate the minimum sample 
size required to estimate detection on of an 
effect of a given size. Power analysis can also be 
used to calculate the minimum effect size that is 
likely to be detected in a paper using a given 
sample size.  
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4 RESULTS AND 
DISCUSSION 
 
There is thought to be a complex interplay 
between skin barrier dysfunction and subsequent 
immunological response in common 
inflammatory disorders of keratinisation such as 
AD and psoriasis. The papers in this work have 
aimed to further delineate the genetic factors 
underlying barrier dysfunction mainly in AD, 
but also to identify whether AD and other 
common disorders of keratinisation may share 
genetic susceptibility factors. 
 
4.1 FILAGGRIN MUTATION 
MAPPING IN ETHIOPIAN 
PATIENTS WITH AD AND IV 
(PAPER I) 
 
Mutations in the FLG gene are considered the 
most significant finding to date underlying the 
barrier impairment seen in AD. At present, more 
than 40 loss-of-function mutations have been 
reported in European and Asian populations, and 
filaggrin deficiency is considered a strong risk 
factor for developing AD (81). The global 
contribution of FLG mutations to the 
development of AD and IV remains to be further 
elucidated; and the mutation spectrum has not 
been established in native African populations. 
In paper I we investigated the role of FLG 
mutations in AD and IV patients from an 
African population. We fully sequenced the FLG 
gene in 40 individuals and genotyped 103 
Ethiopian individuals with AD and/or IV for the 
prevalent European loss-of-function variants. 
Neither European nor Asian variants were 
found. In one patient, a novel FLG mutation was 
discovered (Figure 4). No other mutations were 
found. In addition, no difference in filaggrin 
expression was detected in AD or IV skin 
compared to healthy control skin.  
 
Our results suggest that FLG mutations are rare 
in Ethiopian AD and IV patients compared to 
other described populations. The prevalence of 
FLG mutations is reportedly as high as 17 – 42 
% in European populations with moderate-to-
severe AD (142), and 20 - 30 % of AD patients 
in Asian populations (143). Our result suggests a 
prevalence of ~2-3% among Ethiopian AD 
patients. It has been proposed that FLG 
mutations are population specific (144) and a 
difference in the spectra of mutations has been 
described. A theory is that the FLG mutations 
occurred after the major separation of the 
respective populations (145). We wanted to limit 
the ancestral admixture and focused primarily on 
one distinct population, where the admixture of 
other previously-studied populations was 
expected to be limited. However, extensive 
genetic diversity is described in the African 
population, which restricts what generalizations 
can be made for other African populations than  
the Ethiopian (146). There is also a risk of 
underestimating the full spectrum of FLG 
mutations in this population given the sample 
size of fully sequenced AD and IV patients in 
the paper. 
 
 
Figure 4: Sequence results displaying FLG 
mutation 623del2. A two base pair deletion at 
codon 623 (623del2) (top left) leading to a 
premature stop codon (TGA) at codon 632 (top 
right). Wild type FLG corresponding to codon 
623 marked (GAA) (bottom left) and wild type 
FLG corresponding to codon 632 marked (TAT) 
(bottom right). 
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An interesting question arising is why FLG 
mutations are so prevalent in the European 
population in general, as the overall prevalence 
regardless of symptoms has been estimated to 9 
% (48). A theory is that it could have been of 
evolutionary value to carry a mutation causing a 
more permeable skin barrier. Repeated low-level 
exposure of pathogens to antigen-presenting 
cells in the skin might increase the immunity 
against infections during pandemics, e.g. the 
bubonic plague that wiped out 30-60 % of the 
entire European population (147). This sort of 
balanced selection favoring a heterozygous state 
has been proposed in other conditions such as 
the underlying sickle-cell anemia mutations seen 
in malaria-endemic areas (148). Varying 
susceptibility to malaria between different 
populations has previously been demonstrated 
by polymorphisms in several loci affecting 
immune response pathways (149, 150). This 
genotypic and phenotypic adaptation may also 
play a role in other immune-mediated pathways. 
If the prerequisites for balanced selection 
favoring a more permeable skin barrier have not 
been fulfilled in the African population, this 
could help explain the low prevalence of FLG 
mutations found in Ethiopian AD and IV 
patients. 
 
 
Having FLG mutations in a setting such as 
Africa might even be a disadvantage for a single 
individual, since filaggrin contains numerous 
histidine residues which during filaggrin 
degradation serve as substrates for the formation 
of UCA. UCA has been proposed to act as a 
UV-absorbing substance in the stratum corneum 
(151) and filaggrin deficiency has been 
associated with lower concentrations of UCA in 
skin cultures (152) and in vivo (153). Skin 
cultures have shown that irradiation of filaggrin-
deficient skin results in increased cyclobutane 
pyrimidine dimers and caspase 3 activation; both 
suggesting increased DNA damage and 
apoptosis (152). Thus, individuals with 
filaggrin-deficient skin might be subject to 
increased DNA damage in an environment with 
high UV radiation. 
These theories are so far speculations and our 
findings of a low incidence of FLG mutations in 
the material analyzed might have other 
explanations. Secondary down regulation of 
filaggrin in the absence of mutations has been 
discussed previously (58). However, our IHC 
analysis does not indicate any apparent down 
regulation in lesional skin with the phenotype of 
AD or IV (n=7) compared to healthy control 
skin (Figure 5). The phenotype is of great 
importance, and it has been suggested that the 
absence of both palmar hyperlinearity and 
keratosis pilaris may give a negative prediction 
value of FLG mutations as high as 92 % (154). 
The novel mutation 623del2 was detected in an 
AD patient with palmar hyperlinearity and 
keratosis pilaris. Had our AD material 
comprised more patients with palmar 
hyperlinearity and keratosis pilaris, the 
frequency of FLG mutations might have been 
higher, although in our present paper 65.7 % of 
the sequenced AD and IV patients had at least 
one of these clinical features. It is also premature 
to rule out mutations in the non-coding part of 
the FLG gene or in the processing of the 
precursor profilaggrin, as correct processing is 
important for the functionality of filaggrin (155). 
 
 
In summary, our result indicates that common 
European FLG loss-of-function variants are rare 
in Ethiopian AD and IV patients implying that 
other factors play a more important role for the 
pathogenesis of IV and AD in this ethnic group. 
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Figure 5: Immunohistochemistry of filaggrin 
showing expression in Ethiopian healthy 
control skin, AD skin and IV skin. Staining of 
filaggrin expression was detectable in the 
stratum granulosum of the epidermis in 
representative healthy control skin (a) x100 and 
(b) corresponding x400 magnification of 
highlighted area in (a); AD skin (c) x100 and (d) 
corresponding x400 magnification of highlighted 
area in (c); and IV skin (e) x100 and (f) 
corresponding x400 magnification of highlighted 
area in (e). Hyperplasia of the epidermis is 
visible in AD (c-d); and IV (e-f) skin compared to 
control skin (a-b). Scale bars represent 100 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2 IDENTIFYING THE UNDERLYING 
GENETIC FACTOR IN A PATIENT 
WITH ICHTHYOSIS (PAPER II) 
 
We encountered a Swedish patient with typical 
clinical signs of common ichthyosis of either IV 
or XLI-type. The patient exhibited dry gray-
brown scales especially prominent on the legs 
and the extensor surfaces of the arms. XLI 
occurs predominantly in men and may look 
almost indistinguishable from IV, but skin 
histology and surface pH differ in the two 
conditions (156). To determine the exact cause, 
MLPA was run for the STS gene to rule out XLI, 
and FLG genotyping was performed for the FLG 
mutations described in European population. No 
deletions were found in the coding region of STS 
and no FLG mutations were detected. Direct 
sequencing was subsequently performed for the 
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STS gene. In exon 3 a non-sense mutation was 
found using both forward and reverse primer; a 
one base pair substitution C>T changing 
arginine (CGA) into a premature stop (TGA) 
(Figure 6). 
 
Figure 6: Mutation in the STS gene in a 
patient with ichthyosis. STS sequencing 
results with a one base pair substitution C>T 
introducing stop (TGA) in exon 3 at amino acid 
90 (top) and healthy control showing arginine 
(CGA) at amino acid 90 (bottom).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Schematic overview of domains 
and features of the 583 aa steroid sulfatase 
protein. Novel point mutation site R90X in exon 
3 shown with red arrow, previously described 
mutation sites shown with black arrow (96, 157). 
.  
The STS gene is located on Xp22.3 and encodes 
a 62kDa polypeptide containing 10 exons (158). 
In the skin STS is expressed in the epidermis 
and is thought to have a role in steroid 
production and lipid metabolism (158, 159). STS 
mutations are heterogeneous and in addition to 
the more common deletions there are to our 
knowledge 13 described point mutations 
(Human Gene Mutations Database, 2010-11-23), 
12 in the coding region and one in the non-
coding region. Of these, 10 are missense 
mutations, two represent non-sense and the one 
in the non-coding region affects a splice junction 
site (96, 157). The point mutations are all in 
exons 5 - 10 (Figure 7). Most partial deletions 
are also in this area, however partial deletions 
have also been described in exons 1-5 (157). 
Although the genotypic deficiencies are 
heterogeneous, they all lead to loss of STS 
enzyme activity. This leads to defective 
desquamation through corneocyte retention as 
well as phase separation in the stratum corneum 
through excess STS substrate cholesterol 
sulphate, causing the characteristic phenotype 
(94). Here we present an additional STS  
 
 
 
 
 
 
 
 
 
 
mutation, the most 5’ point mutation yet 
described. This emphasizes the value of 
sequencing the entire gene when the clinical 
picture match that of XLI but no deletions are 
found. 
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4.3 NO ASSOCIATION BETWEEN 
FILAGGRIN MUTATIONS AND 
EARLY ONSET OF PSORIASIS 
(PAPER III) 
 
Both psoriasis and AD are considered to exhibit 
disturbed epidermal barrier function (160). In 
AD, FLG mutations may lead to a defect barrier, 
allowing for per-cutaneous allergen and irritant 
priming and subsequent immunological response 
(88). In psoriasis no association has been found 
with truncating FLG mutations (130, 161) 
although a disturbed skin barrier is evident 
(160). FLG mutations are associated with an 
early onset of the disease in AD (162), and have 
been proposed as a modifying factor in other 
conditions of keratinization such as XLI (96). 
We therefore set out to investigate whether FLG 
mutations has any association with early onset of 
psoriasis.  
 
Table 7: FLG genotyping results in early 
onset psoriasis patients and controls. 
Columns R501X, 2282del4, R2447X and 
S3247X show the presence of four prevalent 
European FLG mutations in early onset psoriasis 
patients and controls. Rows “AA” corresponds to 
homozygous wild type for FLG; “Aa” to 
heterozygous for either common FLG null alleles 
and “aa” to homozygous or compound 
heterozygous for either FLG null alleles. Allele 
frequencies were compared using Fisher’s exact 
test.  
 
The FLG gene was genotyped in all patients and 
controls using allelic discrimination (n=555) and 
sequencing (n=20) (Table 7). We found no 
association to prevalent FLG mutations, and did 
not detect any novel FLG mutations in early 
onset psoriasis patients. This indicates that FLG 
loss-of-function variants should not modify the 
age of onset of psoriasis among our patients and 
that there was no indication of any additional 
prevalent FLG mutation. Nevertheless, as our 
patients displayed mild-to-moderate psoriasis 
and were of European descent, the role of FLG 
mutations in severe psoriasis or for psoriasis 
susceptibility in other populations might be 
different. 
 
Still, lowered levels of filaggrin expression have 
been demonstrated in psoriasis (160). In AD skin 
the presence of Th2-mediated cytokines highly 
expressed in AD skin such as IL4, IL13 and 
IL25 down-regulates the expression of filaggrin 
even in the absence of FLG mutations (50, 58). 
However, the immunological response in 
psoriasis is thought to be more Th1- and Th17-
driven than Th2 (163) and it is possible that 
reduced levels of filaggrin protein in psoriatic 
skin is mainly due to disturbed epidermal 
differentiation, or a consequence of alternative 
gene regulation; but this has to be further 
investigated.  
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4.4 FILAGGRIN GENOTYPE 
DETERMINES MOLECULAR AND 
FUNCTIONAL ALTERATIONS IN 
SKIN OF PATIENTS WITH AD 
AND IV (PAPER IV) 
 
Our objective was to study whether the 
functional and molecular alterations in AD and 
IV skin depend on filaggrin loss-of-function, and 
whether FLG genotype determines the type of 
downstream molecular pathway affected. 
 
Patients with AD and/or IV (n=43) and controls 
(n=15) were recruited from two Swedish 
outpatient clinics and a Swedish AD family 
material with known FLG genotype. They were 
clinically examined and their medical history 
recorded using a standardized questionnaire. 
Blood samples and punch biopsies were taken 
from non-lesional skin and TEWL and skin pH 
was assessed with standard techniques. In 
addition to FLG genotyping, the STS gene was 
analyzed to exclude XLI. Microarrays and qPCR 
were used to compare differences in gene 
expression depending on FLG genotype. 
 
FLG was down-regulated both by microarray 
analysis and qPCR in all AD/IV groups 
compared to the healthy controls (Fig 5). 
Although there was a gradient of down-
regulation depending on FLG genotype with the 
lowest filaggrin expression in patients with FLG 
-/- genotype followed by the FLG +/- genotype, 
the FLG +/+ group also displayed down-
regulation compared to healthy control skin. 
Recent studies have shown that pro-
inflammatory cytokines may modulate the 
expression of filaggrin, which might be one of 
the underlying explanations of our finding (50, 
164). Recent studies have shown that pro-
inflammatory cytokines may modulate the 
expression of filaggrin, which might be one of 
the underlying explanations of our finding (50, 
164).  
 
Many of the genes significantly altered in our 
gene expression analysis map to regions 
previously linked to AD (57), further 
highlighting these regions as candidates for AD 
susceptibility. The distributions of these 
differentially expressed genes in our study 
depended on FLG genotype, where several 
clusters were unique for each group, and others 
overlapped (Fig. 9). Genes from these groups 
were mapped to significantly altered pathways in 
each patient group (Table 8). The functional 
alterations evident from the significantly higher 
TEWL and pH (Fig. 8) in the filaggrin-deficient 
groups may influence the number of induced or 
repressed genes involved in tightly regulated 
processes such as inflammatory response, 
following a more permeable barrier, as well as 
enzymatic activity where the pH level is 
important (19).  
 
The importance of changes in TEWL and pH has 
recently been highlighted in filaggrin deficient 
skin. Reduced levels of filaggrin degradation 
products are proposed to increase TEWL and 
pH, decreasing SC hydration and altering 
enzymatic activity (83, 84). This may account 
for alterations in corneocyte and lipid 
organization within the SC (83). Given the 
frequent phenotypic overlap between dry skin, 
IV and AD (evident in our FLG -/- group as 
well); it is proposed that these functional 
alterations are important for the pathogenesis in 
both IV and AD skin with filaggrin deficiency.  
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Figure 8: Mean trans-epidermal water loss 
(TEWL) (a) and pH (b) and decrease in mRNA 
expression (c) in the AD FLG +/+, AD FLG +/- 
and the AD/IV FLG -/- group. All groups 
compared to a healthy control group. Significant 
changes are denoted with * and ** (p<0.05 and 
p<0.01), respectively. All groups had 
significantly altered filaggrin expression 
compared to the healthy control group with 
qPCR; for the FLG +/+ p=0.043, the FLG +/- 
p=0.001 and the FLG -/- group p=0.001. From 
the array expression results the FLG +/+ group 
was lower but not significant (p=0.59) whereas 
the expression was significantly lower in the FLG 
+/- (p=0.04) and FLG -/- groups (p=8x10
-6
). 
 
 
 
 
 
 
 
 
In support of this hypothesis, our AD patients 
without FLG mutations displayed lower 
functional barrier impairment measured by 
TEWL, lower pH and significantly lower mean 
SCORAD than AD patients with FLG mutations 
(The AD FLG +/+ had significantly lower 
SCORAD than the AD FLG +/- and the AD 
patients in the AD/IV FLG -/- group (p=0.02)). 
In addition, the lowest number of significantly 
altered genes was detected in our AD FLG +/+ 
group. This suggests a correlation between 
number of affected genes, barrier impairment 
and disease severity among included AD 
patients.  
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Figure 9: Top overlapping differentially 
expressed genes in AD skin (a) and heat map 
of transcriptional levels of genes in AD skin 
and controls (b). Genes with altered expression 
in patients with FLG wild type genotype (FLG 
+/+), heterozygote FLG mutation genotype (FLG 
+/-), and homozygote FLG mutation genotype 
(FLG -/-). Clusters containing differentially 
expressed genes in marked regions I-VII are 
corresponding regions in a) and b). A list of p-
values and fold changes for all differentially 
expressed genes are described in 
supplementary Table S1 online for paper IV. 
Hierarchal clustering analysis was performed in 
both the gene (row) and experiment (column) 
dimension. Contrast value for each gene is 
shown, e.g. the standardized mean difference 
between the gene’s expression in the group 
versus overall expression.  
 
 
 
 
 
 
 
Of the many genes previously associated to AD 
(57) several were also dysregulated in our array 
data, such as serine protease inhibitor kazal-type 
5 (SPINK-5), mast cell chymase (CMA1) and 
interleukin 4 (IL-4). Any discrepancies regarding 
expression of inflammatory mediators 
commonly found in AD may, at least in part, be 
due to lower expression of these genes in non-
lesional skin. The molecular mechanisms 
involved in the phenotype of AD following the 
functional barrier impairment in our material 
involve altered pathways such as cytoskeleton 
structure, calcium- and phospatidylinositol 
signaling and ATP binding cassette (ABC) 
transport system (Table 8). It has been suggested 
that filaggrin is of importance for cytoskeleton 
organization by aggregating KIFs; and that 
filaggrin deficiency may cause cytoskeleton 
abnormalities such as perinuclear keratin 
retraction in granular cells (83). KIF 
polymerization is actin-dependent (165) and 
subsequently actin-cytoskeleton aberrations may 
contribute to the peripheral KIF retraction 
previously demonstrated in filaggrin-deficient 
skin (83). 
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Table 8: Top altered molecular pathways 
depending on FLG genotype. All included 
molecules were mapped using KEGG Pathway 
analysis. Presented p-values are uncorrected. 
Significant p-values after Bonferroni correction 
are indicated as * (p-value below 0.05) and ** (p-
value below 0.005). Candidate genes mapped to 
each pathway are outlined in the supplementary 
information online for paper IV. 
 
AD FLG +/+ # genes p-value 
Focal adhesion (hsa04510) 30 1x10
-3
 
Regulation of actin cytoskeleton 
(hsa04810) 
29 6x10
-3
 
ECM-receptor interaction (hsa04512) 14 2x10
-2
 
AD FLG +/- # genes p-value 
ECM-receptor interaction (hsa04512) 29 5x10
-6
** 
Focal adhesion (hsa04510) 52 9x10
-6
** 
ABC transporters (hsa02010) 19 1x10
-5
** 
Regulation of actin cytoskeleton 
(hsa04810) 
47 2x10
-3
* 
Calcium signaling pathway (hsa04020) 37 1x10
-2
 
T cell receptor signaling pathway 
(hsa04660) 
23 4x10
-2
 
Adherens junction (hsa04520) 17 7x10
-2
 
AD/IV FLG -/- # genes p-value 
Phosphatidylinositol signaling system 
(hsa04070) 
54 8x10
-7
** 
Focal adhesion (hsa04510) 118 8x10
-7
** 
ECM-receptor interaction (hsa04512) 57 2x10
-6
** 
Regulation of actin cytoskeleton 
(hsa04810) 
123 3x10
-6
** 
Calcium signaling pathway (hsa04020) 100 4x10
-5
* 
T cell receptor signaling pathway 
(hsa04660) 
64 3x10
-4
 
ABC transporters (hsa02010) 31 3x10
-4
 
Tight junction (hsa04530) 71 7x10
-3
 
 
However, the role of filaggrin in impaired 
intermediate filament aggregation has been 
challenged (152) and other factors than filaggrin 
deficiency may explain the alterations in the 
pathway for the regulation of the actin 
cytoskeleton. Our findings support this, as 
pathways for actin-cytoskeleton regulation were 
altered in all our patient groups including the 
group without FLG mutations. In addition, 
several keratins (including keratin 1 and 10) 
were significantly down-regulated in AD 
patients both with and without FLG mutations. 
As the actin filament system has been suggested 
to be involved in KIF transport (165), it is 
possible that increased actin cytoskeleton 
regulation is a compensatory mechanism 
following lower keratin expression. Altogether, 
our data suggests that both keratin expression 
and KIF regulation are subject to modulation in 
AD skin independently of FLG mutations.  
 
Filaggrin may be involved in calcium 
metabolism in the skin (166), and the calcium 
gradient is important for epidermal 
differentiation. A loss of this gradient increases 
keratinocyte proliferation and decreases 
differentiation (167). Impaired calcium 
metabolism has been demonstrated in other 
conditions where the skin barrier is disrupted, 
such as Hailey-Hailey disease (168) and in 
psoriatic skin (169). Further, defective lipid 
transportation and defects in lamellar body 
extrusion have previously been reported in AD 
(170, 171) and mutations in this pathway may 
cause severe ichthyotic conditions such as HI 
(172). Our filaggrin-deficient groups showed 
alterations in the pathways for calcium signaling 
and for ABC transport system, indicating that 
alterations in these pathways are involved in the 
pathogenesis of IV and AD with filaggrin 
deficiency. 
 
In conclusion, we have demonstrated that 
functional parameters and gene expression in 
molecular pathways in vivo is altered in patients 
suffering from AD and IV and depend on 
filaggrin genotype. Patients with FLG mutations 
display a severe phenotype with impaired barrier 
function measured as increased TEWL, and 
significantly altered pH levels. Furthermore, the 
number of genes with altered expression is 
significantly higher in patients with low or 
absent filaggrin expression. These pathways 
include many genes involved in inflammation, 
epidermal differentiation, lipid metabolism, cell 
signalling and adhesion. 
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4.5 GENETIC ASSOCIATION AND 
EXPRESSION ANALYSIS OF THE 
EPIDERMAL 
TRANSGLUTAMINASES IN AD 
(PAPER V) 
 
The epidermal transglutaminases genes TGM1, 
TGM3 and TGM5 encode cross-linking enzymes 
in the epidermis and map in genomic regions 
that have previously been linked to AD and 
associated phenotypes. We therefore set out to 
characterize the expression and test genetic 
association of the epidermal transglutaminases 
on the defective skin barrier evident in AD. 
Genotyping was performed for 47 SNPs in total 
covering the TGM1, TGM3 and TGM5 locus in 
the Swedish family material. Expression analysis 
of the epidermal transglutaminases was 
performed with qPCR and IHC.  
 
Results of expression analysis of the TGM1, 
TGM3 and TGM5 gene using qPCR showed a 
significantly higher level of TGM3 mRNA in 
lesional skin from AD patients than in skin from 
healthy controls (Fig. 8). IHC analysis indicated 
an increase of TG1 and TG3 expression in a 
majority of lesional skin samples, while only 
some of the non-lesional skin samples appeared 
to have an increase in these proteins compared to 
healthy controls. Further, in lesional skin 
characterized by hyperplasia, TG1 and TG3 
expression was found in several of the 
suprabasal layers, while in skin from healthy 
individuals the proteins was localized in the 
outermost granular layer of the epidermis. No 
apparent differences regarding TG5 expression 
were found (Fig 8). 
 
Expression data presented in our study show that 
the expression of the TGM3 gene is markedly 
increased in the skin of AD patients compared to 
the skin of healthy controls, both at transcript 
level and on protein level (Figure 10). Increased 
protein expression was also evident for TG1 but 
without a significant difference at mRNA level. 
 
PDT revealed a significant genetic association 
for one SNP, rs941505, located in the TGM1 
region. The minor allele was under-transmitted 
to offspring with AD and allergen-specific IgE 
(OR=0.60, CI=0.43-0.84). In accordance with 
this, we also found an association for a 
haplotype tagged by the minor allele of 
rs941505 (Table 9). It is possible that 
individuals carrying the associated TGM1 
haplotype may have a reduced risk of 
developing a skin barrier dysfunction, thereby 
reducing the allergen penetrance in the 
epidermis and the risk of subsequent 
development of AD. However, alternative 
explanations are conceivable and further studies 
are required to fully explain the association. 
 
The MAPPER database (173) positions the 
TGM1 SNP rs941505 in an evolutionarily 
conserved part of the predicted promoter region, 
900 bases upstream of the transcription start site. 
Notably, previous studies have indicated that the 
first 1.6 kilo bases upstream of the gene are 
necessary and sufficient for normal tissue- and 
cell layer-specific expression in transgenic mice 
(174). Analysis in the RAVEN software 
(http://www.cisreg.ca/cgi-bin/RAVEN/a) and 
the MAPPER database suggests that the 
rs941505 SNP alters putative binding sites of 
transcription factors overlapping this position.  
 
The TGM1 gene is positioned in a close (~2.3 
kilo bases) head-to-tail arrangement with the 
Rab geranylgeranyl transferase (RABGGTA) 
gene, and analyzing the LD structure in this 
region shows that a haplotype block including 
the associated SNP extends into this gene. The 
RABGGTA gene encodes the α-subunit of the 
GGTase-II enzyme that attaches geranylgeranyl 
moieties (acting as membrane anchors) on Rab 
proteins (175). The Rab proteins are GTPases 
involved in the regulation of organelle 
biogenesis and vesicle transport (176).  
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To date only one genome wide association study 
(GWAS) exploring AD in the European 
population has been published (72). This study 
did not identify the TGM1 gene region as a 
susceptibility locus. 
 
Table 9: Results of Pedigree Disequilibrium 
Test for the inferred TGM1 haplotypes in the 
Swedish AD families. 
 
1
Haplotype Frequency (HF) in the whole 
material. 
2
Odds ratio (OR) of haplotype relative 
to all the other haplotypes in the same block 
together, 95% confidence intervals in brackets. 
3
Permutated p-values given with brackets, NS = 
non-significant. Haplotypes with a frequency 
below 1.5% have been omitted. 
4
 AD IgE+ 
subgroup of AD patients with allergen-specific 
IgE. 
Looking at the SNPs present on the arrays used 
in the GWAS, including a 200 kb region 
surrounding the associated SNP rs941505, we 
conclude that none of these are in high LD with 
rs941505 (based on the HapMap CEU data set). 
Given the LD and the effect size seen for the AD 
phenotype we estimate that the statistical power 
to detect the rs941505 association was below 
30% in both discovery sets of the GWAS. This 
may explain why this study did not identify the 
TGM1 region as a susceptibility locus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In conclusion, expressional analysis links the 
TGM1 and TGM3 gene to the manifestation of 
AD. Further, the results from the genetic 
analysis suggest that genetic variation at the 
TGM1 locus could be involved in the 
development of the disease. Independent sets of 
patients and controls are now needed to confirm 
the genetic association found in the AD family 
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AD 
IgE+4
 
Block 1  Block 2  Block 3 HF
1
 OR
2
 P  OR P 
G T C C -     -      0.608 1.19 
(1.01-1.39) 
0.87  1.12 
(0.93-1.35) 
0.79 
A C C A -     -      0.174 0.55 
(0.43-0.70) 
0.48  0.95 
(0.75-1.20) 
0.62 
G C T C -     -      0.145 1.04 
(0.84-1.28) 
0.22  1.04 
(0.82-1.33) 
0.24 
G C C C -     -      0.033 0.70 
(0.45-1.07) 
0.17  0.81 
(0.48-1.36) 
0.56 
    - C C A A -      0.570 1.31 
(1.13-1.53) 
0.08  1.29 
(1.09-1.54) 
0.04 
(NS
3
) 
    - C C A G -      0.213 0.93 
(0.79-1.10) 
0.42  0.97 
(0.78-1.19) 
0.76 
    - C C T G -      0.094 0.79 
(0.61-1.01) 
0.06  0.56 
(0.39-0.79) 
0.002 
(0.03) 
    - C T A G -      0.057 0.96 
(0.71-1.30) 
0.84  1.03 
(0.71-1.48) 
0.54 
    - T C A A -      0.055 1.03 
(0.75-1.40) 
0.88  0.88 
(0.60-1.29) 
0.89 
         - T G T A G 0.488 1.16 
(1.01-1.34) 
0.04 
(NS
3
) 
 1.19 
(1.01-1.40) 
0.04 
(NS
3
) 
         - C G T G G 0.198 0.93 
(0.77-1.11) 
0.40  0.93 
(0.74-1.16) 
0.51 
         - C G T A G 0.129 0.90 
(0.72-1.12) 
0.33  0.92 
(0.70-1.78) 
0.49 
         - C G T G A 0.068 0.83 
(0.64-1.10) 
0.20  0.81 
(0.59-1.12) 
0.20 
         - C A T G G 0.058 1.18 
(0.85-1.62) 
0.68  1.00 
(0.66-1.48) 
0.81 
         - C G G G A 0.057 0.84 
(0.59-1.18) 
0.31  0.77 
(0.51-1.17) 
0.22 
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material and further studies are needed to 
identify the actual disease causing variations. 
 
Figure 10: Analysis of the epidermal 
transglutaminases TGM1 (A-D), TGM3 (E-H) 
and TGM5 (I-L) mRNA expression in the skin of 
healthy controls (HC; B;F,J) and the non lesional 
( NL;C,G;K) and lesional (L; D;H;L) skin of AD 
patients. 
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5 CONCLUDING REMARKS 
AND FUTURE 
PERSPECTIVES 
 
The work in this thesis have aimed at further 
delineating the genetic factors underlying barrier 
dysfunction mainly in AD, but also at 
identifying whether AD and other common 
disorders of keratinisation may share genetic 
susceptibility factors. AD is a multifactorial, 
heterogeneous genetic disease resulting from the 
interaction of genes with environmental factors. 
The identification of genetic variants such as the 
FLG mutations underlying epidermal barrier 
dysfunction in patients with AD suggests that, in 
many cases, a primary breakdown in the skin 
barrier is the initial event in the development of 
the disease, followed by a triggered immune 
response. It has been shown that the spectrum of 
FLG mutations differ between populations. Our 
results indicate that FLG loss-of-function variant 
are less common in Ethiopian AD and IV 
patients, and other mechanisms are more 
important for the pathogenesis of IV and AD in 
this ethnic group. Such mechanisms could 
include other environmental or genetic triggers 
of the immune response and involve other 
barrier related genes. FLG mutations may also 
exist in the non-coding regions, or there may 
exist abnormalities in profilaggrin processing. 
Taking the distinct genotype-phenotype 
correlation between IV and FLG mutations in 
Europe and Asia into account, genetic 
associations may be found by analyzing 
additional IV patients, and test any findings in 
our AD case control material. Next generation 
sequencing can be used, by which larger 
genomic regions can be analyzed and possibly 
reveal additional genetic associations. It is also 
possible that IV is less common in the Ethiopian 
population, which needs to be determined by 
further epidemiological studies. 
  
We have also genotyped the FLG gene in 
children with psoriasis to determine whether 
FLG mutations could be associated with 
childhood onset of psoriasis, as shown in AD. 
No association was found, and no novel 
mutations were detected, indicating that FLG 
mutations are not a strong modifying factor for 
the onset of psoriasis. To date, the strongest 
genetic association with psoriasis is with the 
HLA-C and ERAP1 immune-regulatory genes, or 
markers in high LD with these genomic regions. 
Further sequencing of the EDC is needed to 
determine which other genetic variants than the 
LCE3B/LCE3C polymorphisms are contributors 
to the PSORS4 association on chromosome 
1q21, and if other epidermal barrier genes 
outside this locus may predispose to psoriasis 
susceptibility. 
 
The most likely model for the development of 
AD is a gene and environmental dosage effect, 
wherein the combination of genetic and 
environmental factors determines the likelihood 
of developing the disease or determining disease 
severity. Our results have revealed several 
functional and molecular alterations in vivo in 
patients suffering from AD and IV depending on 
FLG genotype. Disease severity of AD, the 
gradient of TEWL and pH are increased in 
patients carrying FLG mutations. Furthermore, 
the number of genes with altered expression was 
significantly higher in patients with low or 
absent filaggrin expression. These pathways 
included many genes involved in inflammation, 
epidermal differentiation, lipid metabolism, cell 
signalling and adhesion. 
 
As the epidermal transglutaminases, TGM1, 
TGM3 and TGM5 encodes important cross-
linking enzymes in the epidermis and map in 
genomic regions that have previously been 
linked to AD and associated phenotypes, we 
characterized the expression and tested whether 
genetic variation influenced AD susceptibility. 
Our findings show that expression analysis links 
the TGM1 and TGM3 gene to the manifestation 
of AD. Increased expression of these enzymes 
may be a reflection of an altered barrier function 
and/or ongoing inflammation. Further, genetic 
analysis suggests that genetic variation at the 
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TGM1 locus could be involved in the 
development of the disease. Our results indicate 
that there is a haplotype, carried by ~19% of the 
individuals, that protects against the 
development of AD and allergen specific serum 
IgE. Independent sets of patients and controls 
are now needed to confirm the genetic 
association found in the AD family material and 
further studies, including sequencing, are needed 
to identify the actual disease causing variations.  
 
The results of the work reported in this thesis 
has provided additional descriptive information 
and further elucidated the pathogenesis 
underlying AD, in particular in relation to 
filaggrin deficiency. However, the genetic basis 
for AD is still largely unknown, and next 
generation sequencing should provide important 
clues in the near future. It is possible that FLG 
will be used as a diagnostic tool for 
individualizing therapy. Studies are currently 
underway investigating the therapeutic potential 
of barrier enhancement such as emollients with 
SC lipids, and there is experimental evidence 
indicating that the FLG gene is amendable to up 
regulation. For AD, early preventive measures 
aiming at repairing the barrier might prevent an 
elicited immune response and subsequent atopic 
march.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36 
 
6 ACKNOWLEDGEMENTS 
 
I would like to express my gratitude to Karolinska 
Institutet where I have studied both as a PhD and 
medical student. I would like to thank all teachers and 
staff who have helped and supported me throughout 
my education. I would also like to especially thank 
the following: 
All participating individuals and their families and 
all co-authors in included papers. 
Maria Bradley, my main supervisor, for accepting 
me as your PhD-student. You have always shared 
your never-ending energy with me and everyone 
around you. You have taught me tremendously about 
research and critical thinking, and shown me that 
research is a lot of fun, and there is a lot of room for 
creativity. You have always cheered me up when 
needed and encouraged me in every situation. You 
are the best possible supervisor I could ever have. 
You have inspired me greatly how to combine an 
exciting life with being a hard-working doctor and 
scientist. 
Carl-Fredrik Wahlgren, my co-supervisor, for 
everything you have taught me and for your belief in 
me. It has been a great pleasure to have the chance to 
learn so much from you, and I hope I have the 
opportunity to continue doing so in the future. You 
have made me develop greatly in the clinical 
dermatology and research fields, but also as a person 
and how to make the best of situations, and to always 
remember to have fun! Your pedagogical skills are 
incomparable and I will always remember your ways 
as a great inspiration.  
Magnus Nordenskjöld, my co-supervisor, for all 
your support and your insightful contributions. You 
have besides helping me on all levels made me laugh 
more times than I can think of with your great sense 
of humour and you have shared your vast knowledge 
reaching way beyond medicine. 
Agne Liedén, my co-supervisor, for all your support. 
It has been a fantastic opportunity to learn from you.  
I have valued your opinions always as “the truth” 
considering your impressive ability to combine 
intelligence with being very accurate in everything 
you say. You have helped me tremendously and I 
would not have done this without you. Also, your 
sense of humor has lightened up many days for me 
and I have always looked forward to our meetings. 
Misi Matura, my mentor, for being such an 
incredibly warm person and for giving me pep-talks 
when I have needed them. 
Annika Sääf for introducing me to CMM and to 
genetic research and for being a great friend. You 
guided me from scratch within genetic research, and 
you have shown a never-ending supply of patience, 
always with a smile. 
Everyone in the writing room; Anna Bremer for 
all the fun times together, for being a great friend 
always keeping me in a good mood and helped me 
when I got stuck; Marie Meeths for being a great 
friend and a great person. Our paths have crossed 
many times, and I hope they will continue to do so. 
Johanna Winberg for always being helpful and in 
such a good mood; Josephine Vincent and Miriam 
Entesarian for contributing to such nice atmosphere; 
Tobias Laurell; Malin Kvarnung; and Xiaoli Feng. 
Monica Mastafa, Aron Luthman, and Edvard 
Nordenskjöld for all good times together in the lab 
and after work. 
Everyone at the Dermatology Clinic at Karolinska 
University Hospital; for creating such a warm 
atmosphere; always being so kind and helpful, and 
making it feel like home. Lena Lundeberg for 
allowing me to start working in the clinic and 
encouraging me; Christoph Martschin for being 
such a great friend and always making me laugh;  
Kristofer Thorslund for always sharing your 
positive energy and for your support for me in South 
Korea that I will always remember; Daniel Nosek for 
being a great person and friend; Maria Lagrelius for 
being such a warm person and for all the help in the 
ward; Enikö Sonkoly for being a great inspiration on 
how to combine clinical work with research; Josefin 
Lysell for being a fantastic friend during these years 
in big and small things, for great collaborations and 
for always being there to discuss with; all the other 
 37 
 
resident doctors I have had the pleasure of meeting 
and working with. The attending doctors for always 
being supportive and helping out; Peter Berg and 
Jan Lapins for many fruitful conversations about 
research and dermatology; Gunilla Färm for being 
such a warm, supportive and helpful person; Toomas 
Talme for inspiring conversations about research; 
Klas Nordlind for being a great organizer and 
providing support during the student courses; Mona 
Ståhle for being a very inspiring person and your 
great sense of humour; Arne Wikström for 
increasing my interest in the dermatology field.; 
Gunilla Ekstrand for your help and advice in all 
situations.  To everyone at SESAM; special thanks to 
Mona Enander; Elisabeth Klingsell and Elisabet 
Wennberg.  
The journal club with Maria Sund-Böhme; Maria 
Bradley; Maria Karlsson; Maria Tengvall-Linder; 
Hanna Eriksson; Desireé Wiegleb-Edström and 
Carl-Fredrik Wahlgren; you have all created a 
great creative atmosphere that I am very thankful I 
have had the opportunity to participate in. 
Lotus Mallbris for your support and helpful advice 
about research and the future. 
Sigrid Sahlén for being an amazing person that 
knows everything about everything. You have been a 
great support at the lab and I cherish all your help 
tremendously. 
Anna-Lena Kastman for being a great coworker and 
friend. Your stainings in a class of their own, but 
above all I will always remember all the great 
conversations we have had about big and small stuff, 
about both work and life. 
Friends and co-workers at CMM; special thanks to 
Tatjana Adamovic for being a very extraordinary 
person; Anna Svenningsson; Sanna von Holst; 
Christina Nyström; Ellen Markljung; Michela 
Barbaro; Ameli Norling; Florian Meisgen; Stanley 
Cheuk; Maria Wikén; Valentina Paloschi; Hovsep 
Mahdessian and Therese Olsson.  
Selim Sengul and everyone at the Core facility at 
CMM.  
Tim Crosfield for excellent work and your warm 
personality. 
Ingrid Kockum for all statistical guidance. 
Everyone at Clinical Genetics; especially Peter 
Gustafsson; Eva Rudd; Britt-Marie Anderlid; 
MaiBritt Giancobini; Margareta Lagerberg and 
Anna Hammarsjö. 
Torborg Hoppe for great collaborations and for 
being such a warm person and for guiding me 
through Uppsala; Hans Törmä, Berit Berne and 
Anders Vahlquist for all you taught me about 
molecular dermatology and gene dermatoses and for 
fantastic support in our collaborations. 
Kassahun Bilcha, Dagnchew Shibeshi and the 
dermatologists at ALERT and GONDAR Hospital, 
Ethiopia. Kassahun you are a great friend and an 
excellent dermatologist and researcher. Thank you for 
teaching me tropical dermatology, for your friendship 
and for taking so well care of me in Ethiopia. 
Irwin McLean; Aileen Sandilands; Karin 
Kroboth; Linda Campbell; Sara Brown and 
Francis Smith at the Epithelial Genetics Group in 
Dundee and Toshi Nomura. Irwin you are a great 
inspiration to me and made me realize that world 
class research and having a good time can be 
combined; Aileen for taking time off your busy 
schedule to teach me with such patience and always 
being so kind and helpful.  
All my friends for always being there for me. You 
know who you are and I love you all. My family for 
always supporting, encouraging and believing in me; 
Mathias, my brother, and Malin, my sister, for your 
unconditional love and support; Thomas, my father, 
for always being there for me and always listening; 
Elisabeth, my mother, everything I do I hope to 
make you proud. I always carry you within me; Moa 
and Leo for always giving me joy and making me the 
proudest uncle in the world; Solveig, my 
grandmother for you support in everything I do; 
Fredrik for being a great friend and brother-in-law.  
Ety for being the sunshine of my life. You make me 
feel invulnerable. 
 38 
 
7 REFERENCES 
 
1. Watson JD, Crick FH. Molecular structure of nucleic acids: 
a structure for deoxyribose nucleic acid. J.D. Watson and 
F.H.C. Crick. Published in Nature, number 4356 April 25, 
1953. Nature. 1974 Apr 26;248(5451):765. 
2. Clamp M, Fry B, Kamal M, Xie X, Cuff J, Lin MF, et al. 
Distinguishing protein-coding and noncoding genes in the 
human genome. Proceedings of the National Academy of 
Sciences. 2007 December 4, 2007;104(49):19428-33. 
3. Strachan T, Read A. Human Molecular Genetics. 3rd 
Edition. London and New York Garland Science; 2003. 
4. GeneTests: Medical Genetics information Resource 
(database online). NCBI, University of Washington, Seattle;  
[2011-11-10]; Available from: http://www.genetests.org. 
5. USNLM. Genetics Home Reference 2011 [2011-12-01]; 
Available from: http://ghr.nlm.nih.gov/. 
6. Haines JaP-WM. Approaches to Gene Mapping in Complex 
Human Diseases: Wiley-Liss Inc.; 1998. 
7. Ring JP, B. Ruzicka, T. Handbook of atopic eczema. 2nd 
Edition. New York: Springer-Verlag Berlin Heidelberg New 
York; 2006. 
8. Hill WG, Robertson A. Linkage disequilibrium in finite 
populations. TAG Theoretical and Applied Genetics. 
1968;38(6):226-31. 
9. Donnelly P. Progress and challenges in genome-wide 
association studies in humans. Nature. 2008;456(7223):728-
31. 
10. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, 
Little J, Ioannidis JPA, et al. Genome-wide association 
studies for complex traits: consensus, uncertainty and 
challenges. Nat Rev Genet. 2008;9(5):356-69. 
11. Ebling F, Rook A, Wilkinson D. Textbook of Dermatology. 
5th Edition 1992. 
12. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, 
Georas SN, Cheadle C, et al. Tight junction defects in 
patients with atopic dermatitis. Journal of Allergy and 
Clinical Immunology. 2011 Mar;127(3):773-86.e7. 
13. Schlüter H, Moll I, Wolburg H, Franke WW. The different 
structures containing tight junction proteins in epidermal 
and other stratified epithelial cells, including squamous cell 
metaplasia. European Journal of Cell Biology. 2007;86(11-
12):645-55. 
14. Hoath SB, Leahy DG. The Organization of Human 
Epidermis: Functional Epidermal Units and Phi 
Proportionality. 2003;121(6):1440-6. 
15. Simpson CL, Patel DM, Green KJ. Deconstructing the skin: 
cytoarchitectural determinants of epidermal morphogenesis. 
Nat Rev Mol Cell Biol. 2011;12(9):565-80. 
16. Krieg T, Aumailley M. The extracellular matrix of the 
dermis: flexible structures with dynamic functions. 
Experimental Dermatology. 2011;20(8):689-95. 
17. Xie Z, Bikle DD. The recruitment of phosphatidylinositol 3-
kinase to the E-cadherin-catenin complex at the plasma 
membrane is required for calcium-induced phospholipase C-
gamma1 activation and human keratinocyte differentiation. J 
Biol Chem. 2007 Mar 23;282(12):8695-703. 
18. Rawlings AV, Harding CR. Moisturization and skin barrier 
function. Dermatol Ther. 2004;17 Suppl 1:43-8. 
19. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, 
Moustafa M, et al. Epidermal Barrier Dysfunction in Atopic 
Dermatitis. J Invest Dermatol. 2009 Jun 4:1892-908. 
20. Candi E, Schmidt R, Melino G. The cornified envelope: a 
model of cell death in the skin. Nat Rev Mol Cell Biol. 
2005;6(4):328-40. 
21. Segre JA. Epidermal barrier formation and recovery in skin 
disorders. The Journal of clinical investigation. 
2006;116(5):1150-8. 
22. Bangert C, Brunner PM, Stingl G. Immune functions of the 
skin. Clin Dermatol. 2011 Jul-Aug;29(4):360-76. 
23. Wollenberg A, Räwer H-C, Schauber Jr. Innate Immunity in 
Atopic Dermatitis. Clinical Reviews in Allergy and 
Immunology.1-10. 
24. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang 
JM. Toll-like receptors in inflammation, infection and 
cancer. Int Immunopharmacol. 2007 Oct;7(10):1271-85. 
25. McInturff JE, Modlin RL, Kim J. The role of toll-like 
receptors in the pathogenesis and treatment of 
dermatological disease. J Invest Dermatol. 2005 
Jul;125(1):1-8. 
26. Kawa A. The role of mast cells in allergic inflammation. 
Respiratory Medicine. 2012;106(1):9-14. 
27. Ermertcan AT, Ozturk F, Gunduz K. Toll-like receptors and 
skin. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):997-
1006. 
28. Wollenberg A, Klein E. Current Aspects of Innate and 
Adaptive Immunity in Atopic Dermatitis. Clinical Reviews 
in Allergy and Immunology. 2007;33(1):35-44. 
29. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, 
Weiland SK, et al. Worldwide time trends in the prevalence 
of symptoms of asthma, allergic rhinoconjunctivitis, and 
eczema in childhood: ISAAC Phases One and Three repeat 
multicountry cross-sectional surveys. Lancet. 2006 Aug 
26;368(9537):733-43. 
30. Schmitt J, Langan S, Stamm T, Williams HC. Core 
Outcome Domains for Controlled Trials and Clinical 
Recordkeeping in Eczema: International Multiperspective 
Delphi Consensus Process. J Invest Dermatol. 2010 Oct 14. 
31. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. 
Working Party's Diagnostic Criteria for Atopic Dermatitis. 
III. Independent hospital validation. Br J Dermatol. 1994 
Sep;131(3):406-16. 
32. Leung DYM, Bieber T. Atopic dermatitis. The Lancet. 
2003;361(9352):151-60. 
33. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier 
BQ, Lockey RF, et al. Revised nomenclature for allergy for 
global use: Report of the Nomenclature Review Committee 
of the World Allergy Organization, October 2003. Journal 
of Allergy and Clinical Immunology. 2004;113(5):832-6. 
34. Flohr C, Johansson SGO, Wahlgren C-F, Williams H. How 
atopic is atopic dermatitis? Journal of Allergy and Clinical 
Immunology. 2004;114(1):150-8. 
35. Hanifin JM. Atopic Dermatitis Nomenclature Variants Can 
Impede Harmonization. J Invest Dermatol. 2011. 
36. Spergel JM, Paller AS. Atopic dermatitis and the atopic 
march. J Allergy Clin Immunol. 2003 Dec;112(6 
Suppl):S118-27. 
37. Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: 
progression from atopic dermatitis to allergic rhinitis and 
asthma. Allergy Asthma Immunol Res. 2011 Apr;3(2):67-
73. 
38. Spergel JM. Epidemiology of atopic dermatitis and atopic 
march in children. Immunol Allergy Clin North Am. 2010 
Aug;30(3):269-80. 
39. Elias PM, Steinhoff M. “Outside-to-Inside” (and Now Back 
to “Outside”) Pathogenic Mechanisms in Atopic Dermatitis. 
J Invest Dermatol. 2008 May;128(5):1067-70. 
40. Novak N, Simon D. Atopic dermatitis – from new 
pathophysiologic insights to individualized therapy. Allergy. 
2011 Jul;66(7):830-9. 
41. Reginald K, Westritschnig K, Linhart B, Focke-Tejkl M, 
Jahn-Schmid B, Eckl-Dorna J, et al. Staphylococcus aureus 
fibronectin-binding protein specifically binds IgE from 
patients with atopic dermatitis and requires antigen 
 39 
 
presentation for cellular immune responses. Journal of 
Allergy and Clinical Immunology. 2011;128(1):82-91.e8. 
42. Suarez AL, Feramisco JD, Koo J, Steinhoff M. 
Psychoneuroimmunology of Psychological Stress and 
Atopic Dermatitis: Pathophysiologic and Therapeutic 
Updates. Acta Derm Venereol. 2011 Nov 21. 
43. Sääf AM, Tengvall-Linder M, Chang HY, Adler AS, 
Wahlgren CF, Scheynius A, et al. Global expression 
profiling in atopic eczema reveals reciprocal expression of 
inflammatory and lipid genes. PLoS One. 2008 
Dec;3(12):e4017. 
44. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier 
T, Fluhr JW. Increased stratum corneum serine protease 
activity in acute eczematous atopic skin. British Journal of 
Dermatology. 2009 Jul;161(1):70-7. 
45. Imokawa G. Lipid abnormalities in atopic dermatitis. J Am 
Acad Dermatol. 2001 Jul;45(1 Suppl):S29-32. 
46. Murata Y, Ogata J, Higaki Y, Kawashima M, Yada Y, 
Higuchi K, et al. Abnormal expression of sphingomyelin 
acylase in atopic dermatitis: an etiologic factor for ceramide 
deficiency? J Invest Dermatol. 1996 Jun;106(6):1242-9. 
47. Pilgram GS, Vissers DC, van der Meulen H, Pavel S, 
Lavrijsen SP, Bouwstra JA, et al. Aberrant lipid 
organization in stratum corneum of patients with atopic 
dermatitis and lamellar ichthyosis. J Invest Dermatol. 2001 
Sep;117(3):710-7. 
48. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, 
Liao H, Lee SP, et al. Common loss-of-function variants of 
the epidermal barrier protein filaggrin are a major 
predisposing factor for atopic dermatitis. Nat Genet. 2006 
Apr;38(4):441-6. 
49. Cork MJ, Robinson DA, Vasilopoulos Y, Ferguson A, 
Moustafa M, MacGowan A, et al. New perspectives on 
epidermal barrier dysfunction in atopic dermatitis: gene-
environment interactions. J Allergy Clin Immunol. 2006 
Jul;118(1):3-21; quiz 2-3. 
50. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, 
DeBenedetto A, et al. Cytokine modulation of atopic 
dermatitis filaggrin skin expression. J Allergy Clin 
Immunol. 2009 Sep;124(3 Suppl 2):R7-R12. 
51. Aileen Sandilands CS, Alan D Irvine and W.H Irwin 
McLean. Filaggrin in the frontline: role in skin barrier 
function and disease. Journal of Cell Science. 2009 
May;122:1285-94. 
52. Descargues P, Deraison C, Bonnart C, Kreft M, Kishibe M, 
Ishida-Yamamoto A, et al. Spink5-deficient mice mimic 
Netherton syndrome through degradation of desmoglein 1 
by epidermal protease hyperactivity. Nat Genet. 2005 
Jan;37(1):56-65. 
53. Vasilopoulos Y, Cork MJ, Teare D, Marinou I, Ward SJ, 
Duff GW, et al. A nonsynonymous substitution of cystatin 
A, a cysteine protease inhibitor of house dust mite protease, 
leads to decreased mRNA stability and shows a significant 
association with atopic dermatitis. Allergy. 2007 
May;62(5):514-9. 
54. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting 
pathogenesis of atopic dermatitis and psoriasis--part I: 
clinical and pathologic concepts. J Allergy Clin Immunol. 
2011 May;127(5):1110-8. 
55. Wilsmann-Theis D, Hagemann T, Jordan J, Bieber T, Novak 
N. Facing psoriasis and atopic dermatitis: are there more 
similarities or more differences? Eur J Dermatol. 2008 Mar-
Apr;18(2):172-80. 
56. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Whynot 
J, Novitskaya I, Cardinale I, et al. Major differences in 
inflammatory dendritic cells and their products distinguish 
atopic dermatitis from psoriasis. J Allergy Clin Immunol. 
2007 May;119(5):1210-7. 
57. Barnes KC. An update on the genetics of atopic dermatitis: 
scratching the surface in 2009. J Allergy Clin Immunol. 
2010 Jan;125(1):16-29.e11. 
58. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran 
B, Deleuran M. IL-25 in Atopic Dermatitis: A Possible Link 
between Inflammation and Skin Barrier Dysfunction? J 
Invest Dermatol. 2010. 
59. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting 
pathogenesis of atopic dermatitis and psoriasis--part II: 
immune cell subsets and therapeutic concepts. J Allergy 
Clin Immunol. 2011 Jun;127(6):1420-32. 
60. Fölster-Holst R, Pape M, Buss YL, Christophers E, 
Weichenthal M. Low prevalence of the intrinsic form of 
atopic dermatitis among adult patients. Allergy. 
2006;61(5):629-32. 
61. Yoshiki T. Extrinsic and intrinsic types of atopic dermatitis. 
Journal of Dermatological Science. 2010;58(1):1-7. 
62. Roguedas-Contios A-M, Misery L. What is Intrinsic Atopic 
Dermatitis? Clinical Reviews in Allergy and Immunology. 
2011;41(3):233-6. 
63. Schultz Larsen F. Atopic dermatitis: a genetic-
epidemiologic study in a population-based twin sample. J 
Am Acad Dermatol. 1993 May;28(5 Pt 1):719-23. 
64. Schultz Larsen F, Holm NV, Henningsen K. Atopic 
dermatitis: A genetic-epidemiologic study in a population-
based twin sample. Journal of the American Academy of 
Dermatology. 1986;15(3):487-94. 
65. Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson 
D, et al. A major susceptibility locus for atopic dermatitis 
maps to chromosome 3q21. Nat Genet. 2000 Dec;26(4):470-
3. 
66. Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley 
AJ, Cox HE, et al. Genetic linkage of childhood atopic 
dermatitis to psoriasis susceptibility loci. Nat Genet. 2001 
Apr;27(4):372-3. 
67. Bradley M, Soderhall C, Luthman H, Wahlgren CF, 
Kockum I, Nordenskjold M. Susceptibility loci for atopic 
dermatitis on chromosomes 3, 13, 15, 17 and 18 in a 
Swedish population. Hum Mol Genet. 2002 Jun 
15;11(13):1539-48. 
68. Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, 
Tan Q, et al. Atopic dermatitis -- a total genome-scan for 
susceptibility genes. Acta Derm Venereol. 2004;84(5):346-
52. 
69. Guilloud-Bataille M, Bouzigon E, Annesi-Maesano I, 
Bousquet J, Charpin D, Gormand F, et al. Evidence for 
linkage of a new region (11p14) to eczema and allergic 
diseases. Hum Genet. 2008 Jan;122(6):605-14. 
70. Enomoto H, Noguchi E, Iijima S, Takahashi T, Hayakawa 
K, Ito M, et al. Single nucleotide polymorphism-based 
genome-wide linkage analysis in Japanese atopic dermatitis 
families. BMC Dermatology. 2007;7(1):5. 
71. Soderhall C, Bradley M, Kockum I, Wahlgren CF, Luthman 
H, Nordenskjold M. Linkage and association to candidate 
regions in Swedish atopic dermatitis families. Hum Genet. 
2001 Aug;109(2):129-35. 
72. Esparza-Gordillo J, Weidinger S, Folster-Holst R, 
Bauerfeind A, Ruschendorf F, Patone G, et al. A common 
variant on chromosome 11q13 is associated with atopic 
dermatitis. Nat Genet. 2009 May;41(5):596-601. 
73. O'Regan GM, Campbell LE, Cordell HJ, Irvine AD, 
McLean WH, Brown SJ. Chromosome 11q13.5 variant 
associated with childhood eczema: an effect supplementary 
to filaggrin mutations. J Allergy Clin Immunol. 2010 
Jan;125(1):170-4 e1-2. 
74. O'Regan GM, Sandilands A, McLean WH, Irvine AD. 
Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2009 
Sep;124(3 Suppl 2):R2-6. 
 40 
 
75. Volz A, Korge BP, Compton JG, Ziegler A, Steinert PM, 
Mischke D. Physical mapping of a functional cluster of 
epidermal differentiation genes on chromosome 1q21. 
Genomics. 1993 Oct;18(1):92-9. 
76. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. 
Genes encoding structural proteins of epidermal 
cornification and S100 calcium-binding proteins form a 
gene complex ("epidermal differentiation complex") on 
human chromosome 1q21. J Investig Dermatol. 
1996;106(5):989-92. 
77. de Guzman Strong C, Conlan S, Deming CB, Cheng J, Sears 
KE, Segre JA. A milieu of regulatory elements in the 
epidermal differentiation complex syntenic block: 
implications for atopic dermatitis and psoriasis. Human 
Molecular Genetics. 2010 April 15, 2010;19(8):1453-60. 
78. Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandilands A, 
Campbell LE, Zhao Y, et al. Loss-of-function mutations in 
the gene encoding filaggrin cause ichthyosis vulgaris. Nat 
Genet. 2006 Mar;38(3):337-42. 
79. Seguchi T, Cui CY, Kusuda S, Takahashi M, Aisu K, 
Tezuka T. Decreased expression of filaggrin in atopic skin. 
Arch Dermatol Res. 1996 Jul;288(8):442-6. 
80. Irvine AD, McLean WH, Leung DY. Filaggrin mutations 
associated with skin and allergic diseases. N Engl J Med. 
2011 Oct 6;365(14):1315-27. 
81. Akiyama M. FLG mutations in ichthyosis vulgaris and 
atopic eczema: spectrum of mutations and population 
genetics. British Journal of Dermatology. 2010;162(3):472-
7. 
82. Irvine AD, McLean WHI, Leung DYM. Filaggrin Mutations 
Associated with Skin and Allergic Diseases. New England 
Journal of Medicine. 2011;365(14):1315-27. 
83. Gruber R, Elias PM, Crumrine D, Lin TK, Brandner JM, 
Hachem JP, et al. Filaggrin genotype in ichthyosis vulgaris 
predicts abnormalities in epidermal structure and function. 
Am J Pathol. 2011 May;178(5):2252-63. 
84. Jungersted JM, Scheer H, Mempel M, Baurecht H, 
Cifuentes L, Hogh JK, et al. Stratum corneum lipids, skin 
barrier function and filaggrin mutations in patients with 
atopic eczema. Allergy. 2010 Jul;65(7):911-8. 
85. Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, 
Rogiers V, et al. Sustained serine proteases activity by 
prolonged increase in pH leads to degradation of lipid 
processing enzymes and profound alterations of barrier 
function and stratum corneum integrity. J Invest Dermatol. 
2005 Sep;125(3):510-20. 
86. Briot As, Deraison Cl, Lacroix M, Bonnart C, Robin Al, 
Besson Cl, et al. Kallikrein 5 induces atopic dermatitis-like 
lesions through PAR2-mediated thymic stromal 
lymphopoietin expression in Netherton syndrome. The 
Journal of Experimental Medicine. 2009;206(5):1135-47. 
87. Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler 
E, Kezic S, et al. Intragenic Copy Number Variation within 
Filaggrin Contributes to the Risk of Atopic Dermatitis with 
a Dose-Dependent Effect. J Invest Dermatol. 2012 
Jan;132(1):98-104. 
88. Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders 
SP, Mangan NE, et al. A homozygous frameshift mutation 
in the mouse Flg gene facilitates enhanced percutaneous 
allergen priming. Nat Genet. 2009 May;41(5):602-8. 
89. Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, 
Robinson DA, Duff GW, et al. Genetic association between 
an AACC insertion in the 3'UTR of the stratum corneum 
chymotryptic enzyme gene and atopic dermatitis. J Invest 
Dermatol. 2004 Jul;123(1):62-6. 
90. Walley AJ, Wiltshire S, Ellis CM, Cookson WO. Linkage 
and allelic association of chromosome 5 cytokine cluster 
genetic markers with atopy and asthma associated traits. 
Genomics. 2001 Feb 15;72(1):15-20. 
91. Akiyama M, Shimizu H. An update on molecular aspects of 
the non-syndromic ichthyoses. Experimental Dermatology. 
2008;17(5):373-82. 
92. Akiyama M. Updated molecular genetics and pathogenesis 
of ichthiyoses. Nagoya J Med Sci. 2011 Aug;73(3-4):79-90. 
93. Russell LJ, DiGiovanna JJ, Rogers GR, Steinert PM, 
Hashem N, Compton JG, et al. Mutations in the gene for 
transglutaminase 1 in autosomal recessive lamellar 
ichthyosis. Nat Genet. 1995 Mar;9(3):279-83. 
94. Elias PM, Crumrine D, Rassner U, Hachem JP, Menon GK, 
Man W, et al. Basis for abnormal desquamation and 
permeability barrier dysfunction in RXLI. J Invest 
Dermatol. 2004 Feb;122(2):314-9. 
95. Brown SJ, McLean WH. One Remarkable Molecule: 
Filaggrin. J Invest Dermatol. 2011 Dec 8. 
96. Liao H, Waters AJ, Goudie DR, Aitken DA, Graham G, 
Smith FJ, et al. Filaggrin mutations are genetic modifying 
factors exacerbating X-linked ichthyosis. J Invest Dermatol. 
2007 Dec;127(12):2795-8. 
97. Ramesh R, Chen H, Kukula A, Wakeling EL, Rustin MHA, 
McLean WHI. Exacerbation of X-linked ichthyosis 
phenotype in a female by inheritance of filaggrin and steroid 
sulfatase mutations. Journal of Dermatological Science. 
2011;64(3):159-62. 
98. Kawashima T, Noguchi E, Arinami T, Yamakawa-
Kobayashi K, Nakagawa H, Otsuka F, et al. Linkage and 
association of an interleukin 4 gene polymorphism with 
atopic dermatitis in Japanese families. Journal of Medical 
Genetics. 1998 June 1, 1998;35(6):502-4. 
99. Liu X, Nickel R, Beyer K, Wahn U, Ehrlich E, Freidhoff 
LR, et al. An IL13 coding region variant is associated with a 
high total serum IgE level and atopic dermatitis in the 
German Multicenter Atopy Study (MAS-90). Journal of 
Allergy and Clinical Immunology. 2000;106(1):167-70. 
100. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar 
D, et al. Genome-wide scan reveals association of psoriasis 
with IL-23 and NF-kappaB pathways. Nat Genet. 2009 
Feb;41(2):199-204. 
101. Hershey GKK, Friedrich MF, Esswein LA, Thomas ML, 
Chatila TA. The Association of Atopy with a Gain-of-
Function Mutation in the alpha-subunit of the Interleukin-4 
Receptor. New England Journal of Medicine. 
1997;337(24):1720-5. 
102. Trembath RC, Lee Clough R, Rosbotham JL, Jones AB, 
Camp RDR, Frodsham A, et al. Identification of a Major 
Susceptibility Locus on Chromosome 6p and Evidence for 
Further Disease Loci Revealed by a Two Stage Genome-
Wide Search in Psoriasis. Human Molecular Genetics. 1997 
May 1, 1997;6(5):813-20. 
103. Strange A, Capon F, Spencer CC, Knight J, Weale ME, 
Allen MH, et al. A genome-wide association study identifies 
new psoriasis susceptibility loci and an interaction between 
HLA-C and ERAP1. Nat Genet. 2010 Nov;42(11):985-90. 
104. Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai 
M, Sasaki S, et al. Association between genetic variants of 
mast-cell chymase and eczema. Lancet. 1996 Aug 
31;348(9027):581-3. 
105. Novak N, Kruse S, Potreck J, Maintz L, Jenneck C, 
Weidinger S, et al. Single nucleotide polymorphisms of the 
IL18 gene are associated with atopic eczema. J Allergy Clin 
Immunol. 2005 Apr;115(4):828-33. 
106. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, 
Plunkett BS, et al. Atopic dermatitis is associated with a 
functional mutation in the promoter of the C-C chemokine 
RANTES. J Immunol. 2000 Feb 1;164(3):1612-6. 
107. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, 
Callis KP, et al. A large-scale genetic association study 
confirms IL12B and leads to the identification of IL23R as 
 41 
 
psoriasis-risk genes. Am J Hum Genet. 2007 Feb;80(2):273-
90. 
108. Weidinger S, Klopp N, Rummler L, Wagenpfeil S, Novak 
N, Baurecht HJ, et al. Association of NOD1 polymorphisms 
with atopic eczema and related phenotypes. J Allergy Clin 
Immunol. 2005 Jul;116(1):177-84. 
109. Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, Klotz M, 
Werfel T, Herz U, et al. The toll-like receptor 2 R753Q 
polymorphism defines a subgroup of patients with atopic 
dermatitis having severe phenotype. J Allergy Clin 
Immunol. 2004 Mar;113(3):565-7. 
110. Lange J, Heinzmann A, Zehle C, Kopp M. CT genotype of 
promotor polymorphism C159T in the CD14 gene is 
associated with lower prevalence of atopic dermatitis and 
lower IL-13 production. Pediatr Allergy Immunol. 2005 
Aug;16(5):456-7. 
111. Prado-Montes de Oca E, Garcia-Vargas A, Lozano-
Inocencio R, Gallegos-Arreola MP, Sandoval-Ramirez L, 
Davalos-Rodriguez NO, et al. Association of beta-defensin 1 
single nucleotide polymorphisms with atopic dermatitis. Int 
Arch Allergy Immunol. 2007;142(3):211-8. 
112. Safronova OG, Vavilin VA, Lyapunova AA, Makarova SI, 
Lyakhovich VV, Kaznacheeva LF, et al. Relationship 
between glutathione S-transferase P1 polymorphism and 
bronchial asthma and atopic dermatitis. Bull Exp Biol Med. 
2003 Jul;136(1):73-5. 
113. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, 
Lawrence R, et al. Gene polymorphism in Netherton and 
common atopic disease. Nat Genet. 2001 Oct;29(2):175-8. 
114. Riveira-Munoz E, He SM, Escaramis G, Stuart PE, 
Huffmeier U, Lee C, et al. Meta-analysis confirms the 
LCE3C_LCE3B deletion as a risk factor for psoriasis in 
several ethnic groups and finds interaction with HLA-Cw6. 
J Invest Dermatol. 2011 May;131(5):1105-9. 
115. Rothnagel JA, Dominey AM, Dempsey LD, Longley MA, 
Greenhalgh DA, Gagne TA, et al. Mutations in the rod 
domains of keratins 1 and 10 in epidermolytic 
hyperkeratosis. Science. 1992 Aug 21;257(5073):1128-30. 
116. Rothnagel JA, Traupe H, Wojcik S, Huber M, Hohl D, 
Pittelkow MR, et al. Mutations in the rod domain of keratin 
2e in patients with ichthyosis bullosa of Siemens. Nat Genet. 
1994 Aug;7(4):485-90. 
117. Jobard F, Lefevre C, Karaduman A, Blanchet-Bardon C, 
Emre S, Weissenbach J, et al. Lipoxygenase-3 (ALOXE3) 
and 12(R)-lipoxygenase (ALOX12B) are mutated in non-
bullous congenital ichthyosiform erythroderma (NCIE) 
linked to chromosome 17p13.1. Hum Mol Genet. 2002 Jan 
1;11(1):107-13. 
118. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, 
Goto M, Arita K, et al. Mutations in lipid transporter 
ABCA12 in harlequin ichthyosis and functional recovery by 
corrective gene transfer. J Clin Invest. 2005 
Jul;115(7):1777-84. 
119. Lefevre C, Bouadjar B, Ferrand V, Tadini G, Megarbane A, 
Lathrop M, et al. Mutations in a new cytochrome P450 gene 
in lamellar ichthyosis type 3. Hum Mol Genet. 2006 Mar 
1;15(5):767-76. 
120. Lefevre C, Bouadjar B, Karaduman A, Jobard F, Saker S, 
Ozguc M, et al. Mutations in ichthyin a new gene on 
chromosome 5q33 in a new form of autosomal recessive 
congenital ichthyosis. Hum Mol Genet. 2004 Oct 
15;13(20):2473-82. 
121. Webster D, France JT, Shapiro LJ, Weiss R. X-linked 
ichthyosis due to steroid-sulphatase deficiency. Lancet. 
1978 Jan 14;1(8055):70-2. 
122. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting 
pathogenesis of atopic dermatitis and psoriasis--Part I: 
Clinical and pathologic concepts. Journal of Allergy and 
Clinical Immunology. 2011;127(5):1110-8. 
123. Lebwohl M. Psoriasis. The Lancet. 2003;361(9364):1197-
204. 
124. Swanbeck G, Inerot A, Martinsson T, Wahlstrom J, 
Enerback C, Enlund F, et al. Age at onset and different types 
of psoriasis. Br J Dermatol. 1995 Nov;133(5):768-73. 
125. Yang YW, Keller JJ, Lin HC. Medical comorbidity 
associated with psoriasis in adults: a population-based study. 
British Journal of Dermatology. 2011;165(5):1037-43. 
126. Hebert HL, Ali FR, Bowes J, Griffiths CE, Barton A, 
Warren RB. Genetic Susceptibility to Psoriasis and Psoriatic 
Arthritis: Implications for Therapy. Br J Dermatol. 2011 
Nov 2. 
127. Griffiths CEM, Barker JNWN. Pathogenesis and clinical 
features of psoriasis. The Lancet. 2007 Jul;370(9583):263-
71. 
128. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao 
W, Dannhauser EN, et al. Deletion of the late cornified 
envelope LCE3B and LCE3C genes as a susceptibility 
factor for psoriasis. Nat Genet. 2009 Feb;41(2):211-5. 
129. Henseler T, Christophers E. Disease concomitance in 
psoriasis. Journal of the American Academy of 
Dermatology. 1995;32(6):982-6. 
130. Zhao Y, Terron-Kwiatkowski A, Liao H, Lee SP, Allen 
MH, Hull PR, et al. Filaggrin Null Alleles Are Not 
Associated with Psoriasis. J Invest Dermatol. 
2007;127(8):1878-82. 
131. Bergboer JGM, Zeeuwen PLJM, Irvine AD, Weidinger S, 
Giardina E, Novelli G, et al. Deletion of Late Cornified 
Envelope 3B and 3C Genes Is Not Associated with Atopic 
Dermatitis. J Invest Dermatol. 2010;130(8):2057-61. 
132. Coto E, Santos-Juanes J, Coto-Segura P, Alvarez V. New 
Psoriasis Susceptibility Genes: Momentum for Skin-Barrier 
Disruption. J Invest Dermatol. 2011;131(5):1003-5. 
133. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. 
Measures used in specifying psoriasis lesion(s), global 
disease and quality of life: a systematic review. J 
Dermatolog Treat. 2007;18(4):223-42. 
134. Ekelund E, Lieden A, Link J, Lee SP, D'Amato M, Palmer 
CN, et al. Loss-of-function variants of the filaggrin gene are 
associated with atopic eczema and associated phenotypes in 
Swedish families. Acta Derm Venereol. 2008;88(1):15-9. 
135. Kunz B, Oranje AP, Labrèze L, Stalder JF, Ring J, A T. 
Clinical Validation and Guidelines for the SCORAD Index: 
Consensus Report of the European Task Force on Atopic 
Dermatitis. Dermatology. 1997;195(1):10-9. 
136. Sandilands A, Terron-Kwiatkowski A, Hull PR, O'Regan 
GM, Clayton TH, Watson RM, et al. Comprehensive 
analysis of the gene encoding filaggrin uncovers prevalent 
and rare mutations in ichthyosis vulgaris and atopic eczema. 
Nat Genet. 2007 May;39(5):650-4. 
137. McGuigan FEA, Ralston SH. Single nucleotide 
polymorphism detection:allelic discrimination using 
TaqMan. Psychiatric Genetics. 2002;12(3):133-6. 
138. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, 
Diepvens F, Pals G. Relative quantification of 40 nucleic 
acid sequences by multiplex ligation-dependent probe 
amplification. Nucleic Acids Res. 2002 Jun 15;30(12):e57. 
139. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis 
and visualization of LD and haplotype maps. 
Bioinformatics. 2005 Jan 15;21(2):263-5. 
140. Huang DW, Sherman BT, Lempicki RA. Systematic and 
integrative analysis of large gene lists using DAVID 
bioinformatics resources. Nat Protocols. 2008 Dec;4(1):44-
57. 
141. Dudbridge F. Pedigree disequilibrium tests for multilocus 
haplotypes. Genet Epidemiol. 2003;25(2):115-21. 
142. Barker JN, Palmer CN, Zhao Y, Liao H, Hull PR, Lee SP, et 
al. Null mutations in the filaggrin gene (FLG) determine 
major susceptibility to early-onset atopic dermatitis that 
 42 
 
persists into adulthood. J Invest Dermatol. 2007 
Mar;127(3):564-7. 
143. Zhang H, Guo Y, Wang W, Shi M, Chen X, Yao Z. 
Mutations in the filaggrin gene in Han Chinese patients with 
atopic dermatitis. Allergy. 2010 Oct 8. 
144. Zhang X, Liu S, Chen X, Zhou B, Liu D, Lei G, et al. Novel 
and recurrent mutations in the filaggrin gene in Chinese 
patients with ichthyosis vulgaris. British Journal of 
Dermatology. 2010;163(1):63-9. 
145. Akiyama M. FLG mutations in ichthyosis vulgaris and 
atopic eczema: spectrum of mutations and population 
genetics. Br J Dermatol. 2009 Dec 2. 
146. Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, 
Shamovsky O, et al. Positive natural selection in the human 
lineage. Science. 2006 Jun 16;312(5780):1614-20. 
147. Irvine AD, McLean WHI. Breaking the (Un)Sound Barrier: 
Filaggrin Is a Major Gene for Atopic Dermatitis. J Invest 
Dermatol.126(6):1200-2. 
148. Weatherall DJ. Phenotype[mdash]genotype relationships in 
monogenic disease: lessons from the thalassaemias. Nat Rev 
Genet. 2001;2(4):245-55. 
149. McGuire W, Hill AV, Allsopp CE, Greenwood BM, 
Kwiatkowski D. Variation in the TNF-alpha promoter 
region associated with susceptibility to cerebral malaria. 
Nature. 1994 Oct 6;371(6497):508-10. 
150. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow 
RW, Berendt AR, et al. A high frequency African coding 
polymorphism in the N-terminal domain of ICAM-1 
predisposing to cerebral malaria in Kenya. Hum Mol Genet. 
1997 Aug;6(8):1357-60. 
151. Zenisek A, Kral JA, Hais IM. Sun-screening effect of 
urocanic acid. Biochim Biophys Acta. 1955 Dec;18(4):589-
91. 
152. Mildner M, Jin J, Eckhart L, Kezic S, Gruber F, Barresi C, 
et al. Knockdown of filaggrin impairs diffusion barrier 
function and increases UV sensitivity in a human skin 
model. J Invest Dermatol. 2010 Sep;130(9):2286-94. 
153. Kezic S, Kammeyer A, Calkoen F, Fluhr JW, Bos JD. 
Natural moisturizing factor components in the stratum 
corneum as biomarkers of filaggrin genotype: evaluation of 
minimally invasive methods. Br J Dermatol. 2009 
Nov;161(5):1098-104. 
154. Brown SJ, Relton CL, Liao H, Zhao Y, Sandilands A, 
Wilson IJ, et al. Filaggrin null mutations and childhood 
atopic eczema: a population-based case-control study. J 
Allergy Clin Immunol. 2008 Apr;121(4):940-46 e3. 
155. Eckhart L, Tschachler E. Cuts by Caspase-14 Control the 
Proteolysis of Filaggrin. J Invest Dermatol. 
2011;131(11):2173-5. 
156. Öhman H, Vahlquist A. The pH gradient over the stratum 
corneum differs in X-linked recessive and autosomal 
dominant ichthyosis: a clue to the molecular origin of the 
"acid skin mantle". J Invest Dermatol. 1998 Oct;111(4):674-
7. 
157. Gonzalez-Huerta LM, Messina-Baas OM, Toral-Lopez J, 
Rivera-Vega MR, Kofman-Alfaro S, Cuevas-Covarrubias 
SA. Point mutation in the STS gene in a severely affected 
patient with X-linked recessive ichthyosis. Acta Derm 
Venereol. 2006;86(1):78-9. 
158. Sugawara T, Nomura E, Hoshi N. Both N-terminal and C-
terminal regions of steroid sulfatase are important for 
enzyme activity. J Endocrinol. 2006 February 1, 
2006;188(2):365-74. 
159. Fernandes NF, Janniger CK, Schwartz RA. X-linked 
ichthyosis: An oculocutaneous genodermatosis. Journal of 
the American Academy of Dermatology. 2010;62(3):480-5. 
160. Huffmeier U, Traupe H, Oji V, Lascorz J, Stander M, 
Lohmann J, et al. Loss-of-Function Variants of the Filaggrin 
Gene Are Not Major Susceptibility Factors for Psoriasis 
Vulgaris or Psoriatic Arthritis in German Patients. J Invest 
Dermatol. 2007;127(6):1367-70. 
161. Thyssen J, Johansen J, Carlsen B, Linneberg A, Meldgaard 
M, Szecsi P, et al. The filaggrin null genotypes R501X and 
2282del4 seem not to be associated with psoriasis: results 
from general population study and meta-analysis. J Eur 
Acad Dermatol Venereol. 2011 May 13. 
162. Brown SJ, Sandilands A, Zhao Y, Liao H, Relton CL, 
Meggitt SJ, et al. Prevalent and low-frequency null 
mutations in the filaggrin gene are associated with early-
onset and persistent atopic eczema. J Invest Dermatol. 2008 
Jun;128(6):1591-4. 
163. Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, 
Pennino D, et al. Mutual Antagonism of T Cells Causing 
Psoriasis and Atopic Eczema. New England Journal of 
Medicine. 2011;365(3):231-8. 
164. Kim BE, Howell MD, Guttman E, Gilleaudeau PM, 
Cardinale IR, Boguniewicz M, et al. TNF-[alpha] 
Downregulates Filaggrin and Loricrin through c-Jun N-
terminal Kinase: Role for TNF-[alpha] Antagonists to 
Improve Skin Barrier. J Invest Dermatol. 2011;131(6):1272-
9. 
165. Kolsch A, Windoffer R, Leube RE. Actin-dependent 
dynamics of keratin filament precursors. Cell Motil 
Cytoskeleton. 2009 Jun Nov;66(11):976-85. 
166. Brown SJ, McLean WH. Eczema genetics: current state of 
knowledge and future goals. J Invest Dermatol. 2009 
Mar;129(3):543-52. 
167. Elias PM, Ahn SK, Denda M, Brown BE, Crumrine D, 
Kimutai LK, et al. Modulations in Epidermal Calcium 
Regulate the Expression of Differentiation-Specific 
Markers. 2002 Nov;119(5):1128-36. 
168. Proksch E, Brandner JM, Jensen J-M. The skin: an 
indispensable barrier. Experimental Dermatology. 2008 
Dec;17(12):1063-72. 
169. Menon GK, Elias PM. Ultrastructural localization of 
calcium in psoriatic and normal human epidermis. Arch 
Dermatol. 1991 Jan;127(1):57-63. 
170. Mathay C, Pierre M, Pittelkow MR, Depiereux E, Nikkels 
AF, Colige A, et al. Transcriptional Profiling after Lipid 
Raft Disruption in Keratinocytes Identifies Critical 
Mediators of Atopic Dermatitis Pathways. J Invest 
Dermatol. 2011;131(1):46-58. 
171. Elias PM, Hatano Y, Williams ML. Basis for the barrier 
abnormality in atopic dermatitis: Outside-inside-outside 
pathogenic mechanisms. Journal of Allergy and Clinical 
Immunology. 2008;121(6):1337-43. 
172. Akiyama M. ABCA12 mutations and autosomal recessive 
congenital ichthyosis: A review of genotype/phenotype 
correlations and of pathogenetic conceptsa. Human 
Mutation. 2010;31(10):1090-6. 
173. Marinescu VD, Kohane IS, Riva A. The MAPPER database: 
a multi-genome catalog of putative transcription factor 
binding sites. Nucleic acids research. 2005 Jan 
1;33(Database issue):D91-7. 
174. Phillips MA, Jessen BA, Lu Y, Qin Q, Stevens ME, Rice 
RH. A distal region of the human TGM1 promoter is 
required for expression in transgenic mice and cultured 
keratinocytes. BMC dermatology. 2004 Apr 5;4:2. 
175. Armstrong SA, Seabra MC, Sudhof TC, Goldstein JL, 
Brown MS. cDNA cloning and expression of the alpha and 
beta subunits of rat Rab geranylgeranyl transferase. The 
Journal of biological chemistry. 1993 Jun 5;268(16):12221-
9. 
176. Pereira-Leal JB, Seabra MC. The mammalian Rab family of 
small GTPases: definition of family and subfamily sequence 
motifs suggests a mechanism for functional specificity in the 
Ras superfamily. J Mol Biol. 2000 Aug 25;301(4):1077-87. 
 
